Fidelity SPDR Advertisement
Home > Boards > US OTC > Miscellaneous >

Kraig Biocraft Laboratories Inc. (KBLB)

KBLB RSS Feed
Add KBLB Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator MU_Redskin1, rayovac812, es1, abomination907, TheEternalChampion, TRUTH
Search This Board:
Last Post: 9/30/2014 11:36:52 AM - Followers: 395 - Board type: Free - Posts Today: 24

 

kraiglabs.com
120 North Washington Square, Suite 805
Lansing, Michigan 48933
Telephone: (517) 336-0807
Email: corporate@KraigLabs.com





Kraig Labs Website for investors.


Click Here to Listen to KBLB Conference Call March 2012

Click Here to Listen to KBLB Conference Call June 2011 

Click Here to Listen to KBLB Conference Call Oct 2010

  Quarterly and Annual Reporting to the SEC is available on the Company's Website and EDGAR. 

 

       Financial Statements        *        SEC Filings       *   

Outstanding Shares as of  May 15, 2014
660,791,572 
A/S 10 Billion

 For issues or questions relating to share certificates or the transfer of securities please contact the company's transfer agent:

Registrar and Transfer Company
10 Commerce Drive 
Cranford, NJ  07016-3572

(800) 866-1340



 

Kraig Biocraft Laboratories, Inc. (KBLB) is the first company with a commercially feasible spidersilk to be mass produced. 
 

Kraig Labs is a biotechnology company focused on the development of commercially significant high performance polymers and technical fibers.  Kraig Lab's focus has been on the production of a transgenic silkworm incorporating specific gene sequences from the golden orb weaving spider.  These specific gene sequences inserted are to enable the silkworm to spin a new recombinant fiber which incorporates spider silk proteins.  With the scientific breakthrough announced on September 29, 2010, Kraig Labs is now working to commercialize the transgenic silkworms to compete in the garment industry silk market.  The value for the chinese raw silk market alone is 3-5 billion per annum.  With the creation of 20 seperate transgenic silkworms, all with unique properties, Kraig Labs is now working at an accelerated pace to build upon their first generation transgenic organisms to develop their second generation of transgenic silkworm incorporating spider silk proteins.  The scientists nearly doubled the strength of the silkworm with these specific spider gene insertions.  Their second generation of transgenics are expected to be complete in 2011.  These second generation organisms are to be compared with the strength, flexibility and resiliency of the native spider in which the gene sequences are derived from.  These fibers which will match the strength of spider silk are expected to compete in the technical textiles market valued in excess of 120 billion per annum.  The 3rd generation organisms are currently in the planning phase.  These organisms are expected to spin fibers exceeding the strength of native spiders and may incorporate gene sequences that release an antibiotic, or to help reduce scarring with use in bandages.

 

Kraig Biocraft Laboratories has a sponsored research and development program with the University of Notre Dame, and the University of Wyoming.  The genetic work is occurring at the University of Notre Dame, headed by Dr Malcolm Fraser, Phd.  The gene sequences are derived from Dr. Randy Lewis's(University of Wyoming) patented gene sequences of the golden orb weaving spider.  Kraig labs is paying for all expenses incurred for this research and development program, and thus Kraig Labs has exclusive global commercialization rights with the technologies developed,  including methods, organisms, and fibers produced.



 



 September 29, 2010 Press Conference Held At Notre Dame
 

 

  

       

       


 

 


Must see Videos:                                  

 

 

 

 

        
Kraig Biocraft Laboratories, Inc. Has Its Breakthrough
 
Scientific Achievement Published


 

 Silkworms Transformed with Chimeric Silkworm/Spider Silk Genes Spin Composite Silk Fibers with Improved Mechanical Properties.
http://www.pnas.org/content/109/3/923.long


 



 



 INDUSTRY / SCIENTIFIC JOURNAL ARTICLES :




 


Jan - Feb Issue: Quality Fabric Of The Month:



Spider Silk Potential Unleashed:
http://www.textileworld.com/Articles/2012/January/Jan-Feb_issue/Departments/QFOM_Spider_Silk.html


Techtextil North America 2012 Back To Pre-Recession Level A Great Indicatory That The Industry Is Growing And Moving Forward:
http://www.textileworld.com/Articles/2012/May/Techtextil_North_America_2012_Back_To_Pre-Recession_Level.html





Hybrid Silkworms Spin Spider Silk -- A First
http://news.nationalgeographic.com/news/2012/01/120103-spiders-silkworms-silk-glowing-science-health/

 

 



Genetically engineered silkworms with spider genes spin super-strong silk
http://blogs.discovermagazine.com/notrocketscience/2012/01/03/genetically-engineered-silkworms-with-spider-genes-spin-super-strong-silk/#.UXQKm0oYmWY





6 Spider-Silk Super Powers:
http://www.popularmechanics.com/science/health/med-tech/6-spider-silk-superpowers#slide-1


Published by MIT

Transgenic Worms Make Tough Fibers:
http://www.technologyreview.com/biomedicine/26623/page1/



Silk Spinning The Genetically Modified Way:
www.labnews.co.uk/features/silk-spinning-the-genetically-modified-way/






Kraig Biocraft Expands Into New Lab:
http://www.innovationintextiles.com/kraig-biocraft-expands-into-new-lab/


Techtextil North America Returns to Pre-Recession Levels:
http://www.innovationintextiles.com/techtextil-north-america-returns-to-prerecession-levels/






Kraig Biocraft Laboratories To Hold an Exhibit at Techtextil North America April 24 - 26th: 
http://techtextil-northamerica-us.messefrankfurt.com/atlanta/en/for_exhibitors/welcome.html


Kraig Biocraft Laboratories' Monster Silkworms Pleased the Crowds at 2012 Techtextil North America:

http://markets.on.nytimes.com/research/stocks/news/press_release.asp?docTag=201205010605PRIMZONEFULLFEED254046&feedID=600&press_symbol=10282627





 

 
    May - June Issue:  The Rise Of Bio Composites:
 
    Composite Manufacturing:
http://www.acmanet.org/CM/index.cfm

          
 
    The Allure of Arachnid Silk Spurs Research:

    http://www.compositesmanufacturingblog.com/2012/05/the-allure-of-arachnid-silk-spurs-research/


                                                                                                                                                                                                                                                                                                      
 






  Kraig Biocraft creates composite spider silk fibre:
http://www.fibre2fashion.com/news/textile-news/newsdetails.aspx?news_id=120153



http://companies.einnews.com/article/193226271/-X2ChKcHzgFvklvk?n=2&code=VXJJ8DfFtxJAh6o_
 

 

   Kraig Biocraft Laboratories Develops "Big Red" Recombinant Spider Silk:
http://www.textileworld.com/Articles/2013/January/Kraig_Biocraft_Develops_Big_Red_Recombinant_Spider_Silk.html

       "This new type of fiber was designed to be a combination of spider silk proteins,

      silkworm silk proteins and protein from an unrelated species," Thompson said.

      "From a genetic perspective, what significantly differentiates this material from

      our Monster Silk™ is the unique spider silk genetic sequence that we used,

      which we designed to increase strength to weight ratios. Another important

      difference is the incorporation of a unique protein, which gives the new

      fiber its designation as 'red.'   - Kim Thompson, CEO, Kraig Biocraft-

         
          -
Strands of Big Red silk fibres in the cocoon -








Commercialising the science of spider silk:
http://ei.wtin.com/2013/01/24/commercialising_the_science_of_spider_silk/

 

 


 

MANAGEMENT

Kim Thompson, Founder and CEO
Kim Thompson, CEO.

As the CEO of the company, Mr. Thompson is the only member of the scientific advisory board who is also
a part of the corporation's management. His formal education lies in the fields of economics and law.
He received his B.A. in Applied Economics from James Madison College at Michigan State University. 
He received his Juris Doctorate from the University of Michigan Law School in 1994.

Mr. Thompson founded Kraig Biocraft Laboratories in his pursuit of the development of new biotechnologies
with industrial applications.  As chairman of the scientific advisory board, he brings a unique perspective,and
acts as the primary liaison between the advisory board and the corporation.

Mr. Thompson brings a wealth of experience in business management and consultation to Kraig. Following
the completion of his undergraduate degree, Mr. Thompson joined California Craftsman, Inc. as a
Vice-President with primary responsibility for both marketing and human resources.

Kim Thompson was the director of business development at Franchise Venture Partners, LLC. He subsequently
joined the firm of Shearson, Lehman, Hutton where he specialized in equity trading and research of small cap
companies. Mr. Thompson received the highest series seven score for all Shearson brokers in his class nationwide.
His experience in those small cap equity markets has proven to be invaluable both in his legal and business successes.

Prior to becoming a public company CEO, Mr. Thompson was the founder and senior litigation partner in a California
commercial law firm where he worked as corporate and litigation counsel to privately held and public companies.
His many accomplishments in corporate law include winning and collecting in full what his firm believes to have been
the largest award of lost profits in a California commercial arbitration up to that time. An important part of his work was
winning victories on behalf of corporate clients in disputes over intellectual property and distribution rights. He has
represented business clients ranging from small start ups and micro caps to Fortune 100 companies.

With a background in business leadership and in advising public and private corporations, Kim Thompson continues
to bring a unique perspective to the successful management of business. His extensive business and legal background
enables him to create practical solutions to business problems and seize opportunities for growth.

Mr. Thompson is a member of the Triple Nine Society for persons with documented genius level IQs (having tested above
the 99.9th percentile). He is also active in the realm of science and invention where he has to his credit a number of
provisional patent applications including innovations in the areas of biotechnology, organic polymers, genetic engineering
and magnetic field manipulation, among others.

Conference Calls with Kim Thompson:

March 2012 KBLB Conference Call

March 2012 KBLB Conference Call (Transcript)

June 2011 KBLB Conference Call

October 2010 KBLB Conference Call



2 Audio Interviews with CEO Kim Thompson:

http://smallcapvoice.com/blog/4-16-08-audio-interview-with-kraig-biocraft-laboratories-inc-otcbb-kblb/

http://smallcapvoice.com/blog/5-21-08-audio-interview-with-kraig-biocraft-laboratories-inc-otcbb-kblb/



June 2011, Interview from Chartpoppers with Kraig Biocraft Laboratories CEO Kim Thompson (transcript):

Chartpoppers Interview with Kim Thompson (CEO, KBLB) June 8th 2011 (transcript)


 
January 2012, Interview from StockRadio.com with Kraig Biocraft Laboratories CEO Kim Thompson (transcript):

http://www.kraiglabs.com/press-releases/Interview%20with%20Kim%20K%20Thompson%20Company%20CEO.htm
 


August 2012, Kim Thompsons Letter to Shareholders:

http://www.kraiglabs.com/press-releases/letter%208%205%202012.htm



April 2013, Kim Thompsons Letter to Shareholders:

https://materials.proxyvote.com/Approved/50075W/20130318/OTHER_160541.PDF





BOARD OF SCIENTIFIC ADVISORS
 

Malcolm. J. Fraser, Jr. Ph.D.

Dr. Fraser received his Ph.D. from Ohio State University, and performed postdoctoral research at both Penn State University and Texas A & M University.
At Texas A & M he was a part of the team which developed the genetic expression system which is now a widely used methodology for producing organic
molecules, including pharmaceuticals, on an industrial scale.

He is the co-inventor of the gene splicing technology "piggyBac", as well as the inventor of various piggyBac improvement patents. It was his work on
piggy Bac which first caught the attention of Kraig Biocraft Laboratories.

He was recently selected as a fellow of the American Association for the Advancement of Science. This was awarded in recognition for his distinguished
contributionsto genetics and transgenesis, and for his discovery of the piggyBac transposable element and derived transgenic vector system.

In 2006, Dr. Fraser was awarded $2.5 million from the Bill and Melinda Gates Foundation to fund "deliverable technologies" in the field of transgenesis,
for the prevention of mosquito born disease.

Dr. Fraser is a member of the faculty at the University of Notre Dame, where he heads the Fraser Laboratory. The focus
of his work is molecular genetics.

He is the author or co-author of numerous scientific articles in the field of genetic engineering and gene manipulation.


Dr. Fraser's Audio interview with Quirks and Quarks Jan 14, 2012 :
http://www.cbc.ca/video/news/audioplayer.html?clipid=2186641369



 




Donald L. Jarvis, Ph.D.

Dr. Jarvis received both his B.S. and M.S. in microbiology at Idaho State University . He received his Ph.D. in Virology at Baylor College of Medicine.
After earning his Ph.D. he trained in molecular cloning at Baylor. In 1987 he undertook postdoctoral studies on glycoprotein biosynthesis at Texas
A&M. In 1989, Dr. Jarvis moved into an independent position at Texas A&M.

In 1998, Dr. Jarvis accepted a position in the Department of Molecular Biology at the University of Wyoming . He received a professorship in 2000.
Dr. Jarvis heads a research laboratory within the University's Department of Molecular Biology which focuses on biochemistry, biosynthesis, and
practical genetic engineering applications. He has approximately eighteen patent applications and intellectual property licensing agreements to
his credit, including biosynthesis technologies and technologies with potential applications for pharmaceutical production.

He is the author and co-author of numerous scientific articles in the fields of biosynthesis, genetic engineering and biochemistry.

Dr. Jarvis's consulting appointments have included:

Novagen Corporation, Madison , WI 1996.

DuPont Agricultural Products, Wilmington , DE 1996-1997.

Invitrogen Corporation, Carlsbad , CA 1999-2002.

GlaxoSmithKline Biologicals, Belgium , 2005.

His recent publications include:

Jarvis, D.L., Hollister, J.R., and Aumiller, J.A. 2003. Development of novel transgenic insect cell lines that support humanized
glycoprotein production by baculovirus expression vectors. BioProcessing J. 2:30-34.

Hollister, J.R., Conradt, H.O., and Jarvis, D.L. 2003. Evidence for a sialic acid salvage pathway in lepidopteran insect cells.
Glycobiology 13:487-495.

Jarvis, D.L. 2003. Humanizing recombinant glycoprotein production in the baculovirus-insect cell expression system. Virology 310:1-7.

Tomiya, N., Howe, D., Aumiller, J.J., Pathak, M., Park, J., Palter, K., Jarvis, D.L., Betenbaugh, M.J., and Lee, Y.-C. 2003. Complex-type
biantennary N-glycans of recombinant human transferrin from Trichoplusia in insect cells expressing mammalian ß1,
4-galactosyltransferase and ß1,2-N-acetylglucosaminyltransferase II. Glycobiology 13:23-34.

Washburn, J.O., Chan, E.Y., Volkman, L.E., Aumiller, J.J., and Jarvis, D.L. 2003. Early biosynthesis of BV envelope fusion protein
gp64 enhances AcMNPV virulence in orally-infected Heliothis virescens . J. Virol. 77:280-290.

van Beek, N., Lu, A., Presnail, J., Davis, D., Greenamoyer, C., Joraski, K., Moore, L., Pierson, M., Herrmann, R., Flexner, L., Foster, J.,
Van, A., Wong, J., Jarvis, D., Hollingshaus, G., and McCutchen, B. 2003. Effect of signal sequence and promoter on the speed of action
of a genetically modified Autographa californica nucleopolyhedrovirus expressing the scorpion toxin LqhIT2. Biological Control, 27:53-64.

Vadaie, N. and Jarvis, D.L. 2004. Molecular cloning of a lepidopteran insect ß1,4N-acetylgalactosaminyltransferase with an unusually
broad substrate specificity, a functional role in N -glycoprotein biosynthesis, and a potential functional role in glycolipid biosynthesis.
J. Biol. Chem. 279:33501-33518.

Zhang, J.-H., Washburn, J.O., Jarvis, D.L. and Volkman, L.E. 2004. AcMNPV early gP64 synthesis mitigates developmental resistance
in orally infected noctuid hosts. J. Gen. Virol. 85:833-842.

Wang, Y., Oberly, L.W., Howe, D., Jarvis, D.L., and Murhammer, D.W. 2004. The effect of manganese superoxide dismutase expression
in baculovirus infected insect cells. Appl. Biochem. Biotech. 119:181-193.

Kost, T.A., Condreay, J.P., and Jarvis, D.L. 2005. Baculovirus:  versatile vectors for protein expression in insect and mammalian cells.
Nature Biotechnology 23:567-575.

Aumiller, J.A., Hollister, J.R., and Jarvis, D.L. 2006. Molecular cloning and functional characterization of ß- N -acetylglucosaminidase genes
from Sf9 cells. Prot. Expr. Purif. 47:571-590.

Hill, D.R., Aumiller, J.J., Shi, X., and Jarvis, D.L. 2006. Isolation and characterization of a baculovirus vector that supports recombinant
glycoprotein sialylation by SfSWT-1 cells cultured in serum-free medium. Bioengr. Biotechnol., 95:37-47.

Shi, X. and Jarvis, D.L. 2006. A new method for the rapid amplification of cDNA ends of extremely GC-rich genes. Analyt. Biochem. 356:222-228.

Shi, X., Harrison, R.L., Hollister, J.R., Fraser, M.J., and Jarvis, D.L. 2007. Construction and characterization of new piggyBac vectors for
constitutive or inducible expression of heterologous gene pairs and the identification of a previously unrecognized activator sequence
in piggyBac . BMC Biotechnol. 7:5.

Shi, X. and Jarvis, D.L. 2007. Protein N-glycosylation in the baculovirus-insect cell system. In M.J. Fraser, G.W. Blissard, and J. Vlak (eds.).
Current Drug Targets, Bentham Press, London (in press).

 


 


 
BUSINESS ADVISORY BOARD

 

Henry Wendt    (announced 11/09/2010)                                                                                                                                                                                                                     

Henry Wendt is the former CEO and Chairman of SmithKline Beecham, one of the world's largest and most successful corporations. He has an unparalleled
track record for fostering and managing corporate growth through mergers and acquisitions, as well as through organic growth and global marketing. In fact,
he is generally recognized as the principal architect of the successful merger that created SmithKline Beecham.

In his term as CEO of the pharmaceutical giant, Wendt focused on a "3 point strategy" to help strengthen the business.
His strategy consisted of increasing support of SmithKline's best products, such as Tagamet, weeding out less profitable products, and increasing shareholder
value. This strategy lead to the successful merger of SmithKline with UK-based Beecham Company. The creation of SmithKline Beecham (SKB), engineered by
Wendt and Beecham's chief, created the world's second largest pharmaceutical company in both prescription and over-the-counter drugs.

In addition to his groundbreaking leadership at SmithKline Beecham, Mr. Wendt literally wrote the book on successful strategies for corporate growth in the global
marketplace, Global Embrace: Corporate Challenges in a Transnational World, a 'must read' for corporate executives.

Mr. Wendt is the Co-Founder of Healthcare Investment Partners, as well as the Founder of Global Health Care Partners.
He is a graduate of Princeton University.


 
Raymond Kutsunai 
(announced 11/22/2010)
 (no photo available)

Raymond Kutsunai's unique accomplishments and lifetime experiences have enabled him to forge a path that has left his mark on history and international
business.

Mr. Kutsunai grew up in pre-statehood Hawaii, the geographical and cultural hub that links North America and Asia . When he was a teenager he was sent to
Hiroshima to study Japanese and renew his family and cultural ties. Unfortunately, this was just prior to the outbreak of the Second World War. He attended
high school in Hiroshima. Unable to return to Hawaii during the war, he attended university in Japan.

Immediately after the war, Mr. Kutsunai was distinctively positioned to assist both the United States and the people of Japan. Upon his homecoming to the
United States , Mr. Kutsunai returned to school and completed his university degree at the University of Michigan .

Mr. Kutsunai subsequently rose rapidly through the ranks at SmithKline & French and was named General Manager of SmithKline & French Laboratories
Japan. He was able to parlay his business instincts and extensive understanding of the Japanese culture and business environment into stunning successes
for the Company's Japanese operations.

As remarkable as Mr. Kutsunai's incredible personal and professional experiences have been, they are exceeded by his loyalty to his family, friends, associates
and country.






Joe Cunning, Ph.D.     (announced 01/14/2011)                                                                                                                                                             

Dr. Joe Cunning is a leading figure in the textile industry and member of the Textile Institute's governing board, with 45 years of experience in the fibers, textile
and apparel industry. He was awarded the Textile Institute's Medal for outstanding contribution to the industry in 2000. In 2010 he was presented with the
Textile Institute's Companion Membership award, as one of fifty living persons who have made a significant impact on the textile industry.

Dr. Cunning completed a highly successful 28 year career at DuPont, where he headed the pioneering research laboratory in Wilmington , and was in charge
of worldwide research on all fiber types. His manufacturing experience included worldwide responsibility for non-woven products, as well as polyester filament
and staple fibers.

In addition to his work on various corporate boards, Dr. Cunning served on the governing boards of the Fiber Society, vice-president of the Textile Institute, the
Technical Advisory Committee, and on the board of governors of the Iowa State University Foundation. In 1992, Cunning was named the National Textile
Center 's (a research consortium of eight universities) first Executive Director, a post he held for 12 years. Dr. Cunning is also the President of Cunning &
Associates, Ltd., a leading textile industry consulting firm.

 

 

 





 


SILK SPINNING THE GENETICALLY MODIFIED WAy



Despite the huge potential of genetically modified animals outside of laboratory research, commercialisation of these animals has been extremely  limited. Numerous factors, including negative consumer perception, regulatory hurdles, and limitations inherent to classical GM technologies, have kept the majority of GM animal applications within the realm of academic research. However genome editing using zinc finger nucleases could help develop new markets for the future commercialisation of GM animals.

Genetic modification is commonplace throughout the life sciences sector, from fundamental research to pharmaceutical testing. GM cellular and animal models are valuable tools for the study of many chronic diseases, the testing of pharmaceutical compounds and the development of new therapeutic strategies. Genetic modification also offers great benefits in vaccine and biopharmaceutical manufacturing, which rely heavily on the use of GM organisms for biomolecule design and production. Modifying the genome of an organism or cell line allows the incorporation of target biomolecules in specific biological contexts, as well as the transfer of a gene product from a low-producing organism to one that can produce on a commercial scale. These applications have been widely accepted for many years, with countless GM organisms approved for medical manufacturing applications by drug regulators in all major countries. Despite this widespread success within the research and pharmaceutical sectors, the use of GM organisms outside of these markets has been limited.

Despite the lack of broad acceptance for most commercial applications of GM animal products, this technology has been able to gain traction in a few market sectors. The most obvious application has been the commercialisation of transgenic animals for the production of biomolecules for therapeutic use. Cattle, sheep and goats have been used for large-scale production of antibodies, steroids and hormones - most notably insulin - for many years. In 2009, GTC Biotherapeutics received US FDA approval for bioproduction of a recombinant human antithrombin. This product - ATryn - is extracted from the milk of transgenic goats, and is the first approved biopharmaceutical to be produced using genetically engineered animals. Although this is a significant breakthrough for the commercialisation of GM animals, it is still within the pharmaceutical industry, and is a natural progression of existing cell-based technologies. Of potentially greater commercial interest is the extension of genetic engineering outside of this sector, into areas such as food production, textiles and even companion animals.

GM crops have been available in many countries since the early 1990s, and numerous cash crops - including sugar beet, soybean, corn and tomatoes - have been modified to improve resistance to disease, increase the rate of growth or enhance nutritional value. However, cultivation of these transgenic crops is generally tightly regulated, particularly within the European Union, and this, together with negative public opinion, has limited the more widespread development of GM technologies.

Similar to GM crops, many of the animals currently under development are intended to confer disease resistance, an application particularly suited to the use of zinc finger nuclease (ZFN) technology. Many diseases can be treated by the targeted deletion or modification of a host gene. With ZFNs, these targets can be modified with no footprint of genetic engineering. Due to the high costs of raising livestock, another area of focus in developing commercial GM animals has been increasing the rate of growth or size of animals. Among the first GM animals likely to be launched is a fast growing salmon from AquaBounty. The AquAdvantage Salmon is designed to reach market size in half the time of a wild type salmon, reducing costs for fish farmers and limiting the environmental impact of salmon farming by avoiding the need for ocean pens.

Although genetic engineering of animals for food is primarily driven by economic pressures, GM technologies have also been used in the companion animals market. In this sector, genetic modification can be used for practical purposes - such as the creation of hypoallergenic animals or the correction of heritable congenital defects which have arisen though inbreeding - or for purely cosmetic purposes, such as GloFish. The first example of a GM pet, GloFish are fluorescent zebrafish (Danio rerio) that have had genes encoding naturally fluorescent proteins (GFP, YFP, RFP) inserted into their genome. Developed by a group at the National University of Singapore, GloFish were originally created to develop live detection systems for water pollution. They were introduced as pets in the United States in 2003 following over two years of extensive environmental research and consultation. In Europe however, the sale and possession of GloFish is prohibited by rigorous legislation concerning the use of GM technologies.

 By allowing precisely targeted insertion of spider genes and concomitant removal of endogenous silkworm silk genes at the same locus, ZFN technology offers the potential for development of transgenic silkworms which will produce native spider silk at commercially viable levels

Perhaps even more interesting from a commercial perspective is the use of GM animals in the manufacture of textiles. Silkworms - actually the larval form of the silkmoth Bombyx mori - have been used for the production of silk for thousands of years, with natural silk still produced by the cultivation of silkworms today. Silkworm cocoons are unwound to create linear silk threads, then re-spun into textiles in much the same way as cotton. Although the applications of silkworm silk are numerous, due to their unique physical and chemical properties, there is also widespread interest in the silks of several other insects.

Spider silk, in particular, offers numerous possibilities within the technical textiles industry, due to its incredible tensile strength and elasticity; characteristics which have not yet been replicated in synthetic materials. Like all insect silks, spider silk fibres consist of repetitive units of protein crystals separated by less structured protein chains. The exact properties and composition of each spider silk vary with its intended function. Major Ampullate or dragline silk, for example, is relatively hydrophobic with very high tensile strength and toughness, as it is used to form the outer rim and spokes of a web. In contrast, hydrophilic capture spiral silks, which form the inner structures of the web, are sticky and highly elastic to effectively entrap prey. This high degree of variability offers enormous potential for the textiles industry, raising the possibility of tailoring the properties of silk to create advanced technical fabrics, for applications such as bulletproof vests, parachute canopies and automobile airbags; biomedical applications, including sutures and tendon and ligament repair; new fabrics, for sportswear and clothing; and even microelectronics.

Although the use of spider silks for microsutures has recently been reported, more widespread application of spider silk technologies is currently limited by the difficulty in producing silks on a commercially viable scale. This is due to the difficulties of rearing spiders in large numbers, due to their highly territorial and cannibalistic nature. As a result, the harvesting of spider silk fibres is extremely time consuming and labour intensive, with production of the only known spider silk garment - an 11 foot by 4 foot shawl made from golden orb spider silk - taking 150 people over five years to produce and costing in excess of £300,000!
.

To overcome these
 limitations, and allow future development of spider silk technologies, an alternative strategy for spider silk production is required. This makes spider silk production an obvious candidate for genetic modification, inserting spider silk genes into the genome
of other silk-making insects for bioproduction.  For example, random insertion of orb spider silk genes into silkworms has allowed production of hybrid spider/silkworm silk using traditional silkworm farming strategies. The resulting hybrid silk contains approximately 10% spider silk
and has greater strength and durability than native silkworm silk, raising the possibility of using transgenic silkworms to produce pure spider silks.


Though straightforward in principle, the exchange of native silkworm genes for spider silk genes, alongside more widespread exploitation of genetic engineering, has been limited by the inherent restrictions of conventional GM technologies.
The generalised process of modifying an organism requires several capabilities, including:

  • an ability to synthesise or clone the sequence of interest (if transferring genetic information);
  • the capacity to grow and maintain a population of the organism of interest;
  • access to the genome of the organism of interest;
  • a mechanism to select animals that have received the modification of interest.
 

While many different techniques exist for accomplishing each of these steps, most GM technologies offer a compromise between the efficiency of the technique and the ability to accurately and precisely target the locus of interest. Viral genomic delivery technologies effectively deliver nucleic acids to cells and organisms, but fall short on ability to target specific regions of the genome, generally only allowing random insertion of genetic material. In comparison, transposase technologies allow a greater degree of targeting, but leave unwanted traces of exogenous DNA in their wake. Other methods involve the introduction of naked DNA into the cell, which results in insertion into the genome at very low frequencies, usually at random, limiting this approach to organisms that can be economically cultivated at high densities and screened in large numbers. Simply put, most techniques for genetic manipulation are random, inefficient and leave a 'footprint' of foreign DNA. While this is usually tolerated in basic research, it is not acceptable for most commercial applications, and has been a major hurdle for GM animal technologies to date.

The advent of zinc finger nuclease (ZFN) technology represents a significant breakthrough for commercialisation of GM animal products, offering precisely targeted, efficient genome editing for the first time. Commercially available through Sigma Life Science under the CompoZr brand, this technique can be used to create permanent and heritable changes to an organism of interest.

This high degree of variability offers enormous potential for the textiles industry, raising the possibility of tailoring the properties of silk to create advanced technical fabrics

Credit Nir Nussbaum

ZFNs are a class of engineered DNA binding proteins that facilitate targeted editing of the genome by creating double-strand breaks at user-specified locations. These breaks stimulate the cell's natural DNA repair mechanisms - homologous recombination (HR) and non-homologous end joining (NHEJ) - which can be exploited to achieve rapid and permanent site-specific modification of the desired genes. While HR can be used to insert foreign DNA sequences, NHEJ allows the cell's natural processes to create precisely targeted mimics of natural mutations which leave no traces of foreign DNA. Unlike previous techniques, ZFNs offer excellent sequence specificity, binding 24 to 36 base pair target sequences to virtually eliminate off target effects, and are able to achieve modification rates exceeding 20 %, well above rates for most other technologies.

The technique is already being used to create transgenic silkworms for spider silk production. By allowing precisely targeted insertion of spider genes and concomitant removal of endogenous silkworm silk genes at the same locus, ZFN technology offers the potential for development of transgenic silkworms which will produce native spider silk at commercially viable levels.

GM technologies have revolutionised the research world and have great potential in a variety of commercial applications, but have been limited by the inherent restrictions associated with historical GM technologies. The main drawback of these technologies is their inability to accurately and efficiently target genes of interest, instead relying on random insertion of genetic material into host genomes. These limitations result in the need for extensive and costly screening to identify animals with correct transgene expression (without compromising the viability of the animal), and also result in the co-expression of both the transgene and native homologues already present.

The advent of ZFN technology signifies the beginning of an exciting new chapter in the world of genetic modification, allowing precise, targeted and efficient genome editing for the first time. Production of native spider silk using transgenic silkworms is just one example of the potential commercial applications of this innovative technology, taking us one step closer to the reality of industrial scale biomanufacturing and paving the way for an entirely new spectrum of environmentally friendly materials.

Authors:
Joseph Bedell and Brian Buntaine
Commercial Animal Technologies Group, Sigma Advanced Genetic Engineering (SAGE) Labs, Sigma Life Science

 

 

 

Photos:  Magnified view of transgenic silk, silkworm ready to spin, spun silkworm cocoons and silk made with spider silk sequences.

 

   May 9, 2014



June 18, 2014 - Spider Silk Textile-[First Photos]


monster-silktm-woven-textile-0monster-silktm-woven-textile-1

monster-silktm-woven-textile-magnified-84x_0monster-silktm-woven-textile-magnified-300x_0

monster-silktm-woven-textile-magnified-300x-1_0monster-silktm-woven-textile-magnified-600x_0
 

HEADLINES FOR KRAIG BIOCRAFT LABORATORIES / (KBLB):

 


University of Notre Dame and Kraig Biocraft Laboratories Create Artificial Spider Silk Breakthrough 


September 07, 2010
Source:
http://www.marketwire.com/press-release/kraig-biocraft-laboratories-inc-announces-that-it-has-successfully-created-transgenic-1314311.htm




Kraig Biocraft Laboratories Announces Results at Join Press Conference at the University of Notre Dame


SepraigkJKjfdSeptember 29, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-results-at-joint-press-conference-1327097.htm




Kraig Biocraft Laboratories Announces Patent Filing on Artificial Spider Silk Breakthrough

September 30, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-patent-filing-on-artificial-spider-silk-breakthrough-1327601.htm




Kraig Biocraft Laboratories Announces Application for Trademark of Spider Silk Brands


October 5, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-application-trademark-spider-silk-brands-1329547.htm




Kraig Biocraft Laboratories Changes Ticker To KBLB.PK


October 7, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-changes-ticker-to-kblbpk-1331748.htm




Kraig Biocraft Laboratories Shareholder Conference Call Today, Friday, October 8, 2010


October 8, 2010
Source:  http://www.marketwire.com/press-release/kraig-biocraft-laboratories-shareholder-conference-call-today-friday-october-8-2010-1332000.htm




KBLB (Kraig Biocraft Laboratories) Data Feed Was Temporarily Disrupted Last Thursday, October 7, 2010


October 10, 2010
Source: http://www.marketwire.com/press-release/kblb-kraig-biocraft-laboratories-data-feed-was-temporarily-disrupted-last-thursday-october-1332536.htm




Kraig Biocraft Laboratories Posts Recording of CEO's Shareholder Conference Call Regarding Spider Silk Technology Breakthrough


October 12, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-posts-recording-ceos-shareholder-conference-call-regarding-1332988.htm




Kraig Biocraft Laboratories to Employ Artificial DNA for the Development of Its Next Generation of New Materials for the Technical Textile Market


October 19, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-employ-artificial-dna-development-its-next-generation-new-1337116.htm




Kraig Biocraft Laboratories Announces That Henry Wendt Has Joined Its Business Advisory Board


November 9, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-that-henry-wendt-has-joined-its-business-advisory-1349449.htm




Kraig Biocraft Laboratories Files 3rd Quarter Financial Statement Reflecting a Fifty Percent Reduction in Total Corporate Liabilities


November 18, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-files-3rd-quarter-financial-statement-reflecting-fifty-percent-1355837.htm




Kraig Biocraft Laboratories Announces That Raymond Kutsunai Joined Its Business Advisory Board


November 22, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-that-raymond-kutsunai-has-joined-its-business-1357617.htm




Kraig Biocraft Laboratories Releases Video of the Company's Technology Breakthrough


November 30, 2012
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-releases-video-of-the-companys-technology-breakthrough-1361164.htm




Kraig Biocraft Laboratories' CEO Issues Corporate State of Affairs Letter


December 07, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-ceo-issues-corporate-state-of-affairs-letter-1364821.htm




Kraig Biocraft Laboratories Post New Video on the Company Website


December 31, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-ceo-issues-corporate-state-of-affairs-letter-1364821.htm




Joe Cunnings Joins Kraig Biocraft Laboratories Business Advisory Board


January 24, 2011
Source: http://www.marketwire.com/press-release/joe-cunning-joins-kraig-biocraft-laboratories-business-advisory-board-1384153.htm

 

 

Sigma-Aldrich and Kraig Biocraft Laboratories Successfully Negotiate
License Agreement

 


Tuesday, April 12th, 2011
Source: http://www.marketwire.com/press-release/sigma-aldrich-kraig-biocraft-laboratories-successfully-negotiate-license-
agreement-pinksheets-kblb-1501105.htm


Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announced today that the Company has entered into a licensing
agreement with biotechnology giant Sigma-Aldrich (NASDAQ: SIAL), Inc.


Kraig has successfully negotiated a license to use Sigma-Aldrich's powerful zinc finger technology to accelerate its scientific 
research and product development, along with an option to commercialize the resulting biomaterials in the textile and biomedical
fields.


Under the terms of the agreement announced today, Sigma will provide Kraig with its proprietary genetic engineering tools and
expertise in zinc finger nuclease to enable Kraig to significantly accelerate its product development. In addition to providing the
customized tools and technological know-how, Sigma has granted Kraig an option for a commercial license to use the technology
in the textile and biomedical markets. Sigma has agreed that upon exercise of the option Kraig will have exclusive commercial rights
to use Sigma ZFNs in conjunction with the insertion of more than two hundred proprietary spider silk sequences previously licensed
by Kraig from a third party into the silkworm genome. Sigma-Aldrich will be creating customized zinc fingers for Kraig's use in its
development of spider silk polymers and technical textiles.

"Sigma-Aldrich's proprietary zinc finger technologies are extremely powerful tools which enable very precise genetic targeting," said
Kraig's CEO Kim Thompson.
"We are convinced that this technology is the key to creating advanced new products and materials. We believe that when these
customized tools are delivered by Sigma in the coming weeks, the technology will enable us to rapidly and precisely target specific
gene sequences for the creation of stronger fibers, advanced textiles and new bio-materials."


"ZFN technology has been revolutionary in genome engineering for various applications, including animal models of disease,
engineering of biopharmaceutical production systems, academic research and therapeutics," said Dr. Joseph Bedell, Director
of Sigma's Commercial AnimalTechnologyGroup. "Spider silk production is just the first example of a commercial animal 
application for this exciting technology."

"Kraig has the utmost confidence in the power of Sigma's zinc finger technology," said Mr. Thompson. "Sigma's agreeing to provide
this technology by virtue of the licensing agreement to Kraig, is a real boost for us, and for the future of bio-materials and spider silk
technology. We negotiated this agreement not only to accelerate our development of advanced materials, but also because I believe
that Sigma's zinc finger technology will reinforce Kraig's competitive advantage in the field of bio-materials and advanced silk polymers.
Kraig Biocraft Laboratories expectation is that the combination of Sigma-Aldrich's revolutionary technology
and know-how, coupled with Kraig's proprietary bio-materials technology and know-how, will create synergies that will benefit both 
companies.




Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are
used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key
components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science
companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its
products. Sigma-Aldrich operates in 38 countries and has 7,900 employees providing excellent service worldwide. Sigma-Aldrich is
committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For
more information about Sigma-Aldrich, please visit its award-winning Web site athttp://www.sigma-aldrich.com.

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with
implications for the global textile industry. For further information please visitwww.KraigLabs.com.

Statements in this press release about the company's future and expectations other than historical facts are "forward-looking
statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be
no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be
identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "hopes," "develops," "researching," "research,"
"potential," "implications," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the
Company's business  strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements.
All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially
from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable
products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to
meet the financial obligations of its business  plan and to fund its continuing operations.

Contact:

Ben Hansel

(720) 288-8495

Email Contact

    benhansel@yahoo.com




Kraig Biocraft Laboratories Announces Shareholder Conference Call
Advisory


April 20, 2011
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-shareholder-conference-call-advisory-
pinksheets-kblb-1504541.htm




Kraig Biocraft Labs. to Hold Shareholder Conference Call to Discuss
Laboratory, Technical and Commercialization Updates

May 25, 2011
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-hold-shareholder-conference-call-discuss-laboratory
-technical-pinksheets-kblb-1518617.htm

 
 
 
 

Kraig Biocraft Laboratories Announces the Successful Creation of New Commercial
Hybrid Transgenic Silkworms


Independent Testing Confirms That the New Hybrids Are Producing Recombinant Silk Which
Significantly Exceeds Traditional Silk in Both Elasticity and Tensile Strength.


May 31, 2011

Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-successful-creation-new-commercial-hybrid-transgenic-pinksheets-kblb-1520365.htm



Dr. David Kaplan Joins Kraig Biocraft Laboratories Scientific Advisory Board *
(*Dr. David Kaplan subsequently withdrew from Kraig Biocraft Laboratories' Scientific Advisory Board)
June 6, 2011
Source: http://www.marketwire.com/press-release/dr-david-kaplan-joins-kraig-biocraft-laboratories-scientific-advisory-board-pinksheets-kblb-1522809.htm




Kraig Biocraft Laboratories to Host a Shareholder Conference Call Later Today
Company Founder and CEO, Kim Thompson, to Host Conference Call for Shareholders and All Interested Parties

June 10, 2011
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-to-host-a-shareholder-conference-call-later-today-pinksheets-kblb-1525259.htm



Kraig Biocraft Announces Interview With CEO on Chartpoppers

June 8, 2011
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-interview-with-ceo-on-chartpoppers-pinksheets-kblb-1524084.htm



Kraig Biocraft Laboratories Posts Copy of Shareholder Conference Call on Company Website
Kraig Receives First Shipment of Zinc Fingers From Sigma-Aldrich

June 14, 2011

Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-posts-copy-shareholder-conference-call-on-company-website-pinksheets-kblb-1526210.htm



Kraig Biocraft Laboratories Announces $1.5 Million Agreement With Calm Seas Capital
June 30, 2011
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-15-million-agreement-with-calm-seas-capital-pinksheets-kblb-1533602.htm



Kraig Biocraft Laboratories Announces the Completion of Its First Zinc Finger Micro-Insertions
The Company's First Zinc Finger Technology Silkworms Achieve High Hatch Rate

July 5, 2011
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-completion-its-first-zinc-finger-micro-insertions-pinksheets-kblb-1534346.htm



Kraig Biocraft Laboratories Completes Scheduled Second Round of Micro-Insertions Using Zinc Finger Technology
Kraig Advances Zinc Finger Technology to Modify Previously Disclosed Monster Silk

August 8, 2011

Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-completes-scheduled-second-round-micro-insertions-using-pinksheets-kblb-1546801.htm

 

Kraig Biocraft Laboratories, Inc. Signs Spider Silk Commercial License Agreement With the University of Notre Dame


New agreement makes notre dame a kraig shareholder

November 3, 2011
Source:
http://www.marketwire.com/press-release/kraig-biocraft-laboratories-inc-signs-spider-silk-commercial-license-agreement-with-otcqb-kblb-1581536.htm


Kraig Biocraft Laboratories Announces Creation of Seven New Strains of Transgenic Silkworms Using Zinc Finger Nuclease Technology
New Development Seen as a Major Leap in the Creation of Next Generation Spider Sik Technology

November 14, 2011
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-creation-seven-new-strains-transgenic-silkworms-otcqb-kblb-1586643.htm



Kraig Biocraft Laboratories to Host Shareholder Conference Call Regarding Product, Scientific and Commercialization Developments
December 2, 2011
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-host-shareholder-conference-call-regarding-product-scientific-otcqb-kblb-1593953.htm



Kraig Biocraft Laboratories Announces Filing of International Patent Application for Spider-Silk and Transgenic Silkworm Technologies.
December 8, 2011
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-filing-international-patent-application-spider-pinksheets-kblb-1596145.htm



Kraig Biocraft Laboratories Recieves New Custom Zinc Finger Configurations for Advanced Fibers Development
December 12, 2011
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-receives-new-custom-zinc-finger-configurations-advanced-otcqb-kblb-1597122.htm




Kraig Biocraft Laboratories Announces Peer Reviewed Publication of Spider Silk and Transgenic Silkworm Breakthroughs 
Scientific Study of the Creation of Fusion Fibers and Transgenic Silkworm Is Published in the Journal Proceedings of the National Academy of Sciences

SOUTH BEND, IN -- (Marketwire - Jan 5, 2012) - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (PINKSHEETS: KBLB) is very happy to start the New Year by announcing that the Journal Proceedings of the National Academy of Sciences published a peer- reviewed scientific article describing the breakthrough creation of a spider silk fusion fiber, which was achieved by university scientists within the University of Wyoming and the University of Notre Dame, who are working cooperatively with Kraig Biocraft Laboratories.

The article is the first peer-reviewed scientific publication describing the creation of transgenic silkworms, which have been specifically designed to spin a spider/silkworm silk fusion fiber.  The article's abstract states, "these composite fibers were, on average, tougher than the parental silkworm silk fibers and as tough as native dragline spider silk fibers.  These results demonstrate that silkworms can be engineered to manufacture composite silk fibers containing stably integrated spider silk protein sequences, which significantly improve the overall mechanical properties of the parental  silkworm fibers." 

"The fact that a publication as prestigious as Proceedings of the National Academy of Sciences has chosen to publish these results speaks for itself as to the significance to the scientific breakthrough, "said Company founder and CEO, Kim K. Thompson.   "When I founded Kraig many people in both business and scientific community said that what we were setting out to do was impossible. By maintaining a focused vision and by recruiting the very best minds in molecular biology, we have made the impossible a tangible reality."

"Congratulations to the scientific team as well as to the University of Notre Dame and the University of Wyoming.  They deserve the accolades they are receiving with this publication,"continued Thompson.  "Our next steps are to commercialize these developments while accelerating our development of even more advanced products.  The commercial license agreement we signed in the fourth quarter of 2011 was an essential element of the former.  As we move toward commercialization of these fibers, we are simultaneously moving into an advanced stage in the development of new, second generation spider silk polymers."

The scientific article described above is published, online before print January 3,2012, by the scientific journal Proceedings of the National Academy of Sciences, titled,  "Silkworms Transformed with Chimeric Silkworm/Spider Silk Genes Spin Composite Silk Fibers with Improved Mechanical Properties."

"The recent publication of the analysis of genetically engineered silkworms to produce chimeric spider silks with properties of increased strength and flexibility in the prestigious journal Proceedings of the National Academy of Science represents a significant vindication of our methodology for genetically engineering and producing commercial quantities of novel protiens for medical, structural, and textile fabrics, "said Dr. Malcom Fraser.  "If it were not for Kraig Biocraft Laboratories initiating this project and bringing the technologies together these results may never have materialized."

"The work is the culmination of a research effort begun more than 10 years ago with an internal award from the University of Notre Dame to my lab to develop silkworm transgenics capabilities, a two year NIH R21 grant awarded to Dr. Jarvis, Lewis, and myself, and several years of supplemental funding from Kraig Biocraft Laboratories,"Fraser continued.  "The success of this research would have been impossible without the ability to carry out silkworm transgenics, mastered by Bong-Hee Sohn and Young-Soo Kim in the Fraser lab at the University of Notre Dame.  This manuscript was published after an in depth peer review process, and was deemed by the publishers as a newsworthy article of the issue in which it appears, further indicating its relative importance to science and technology."

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories, Inc. (KBLB)  (www.KraigLabs.com) is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of jurisdiction. 

Contact:
Ben Hansel
Hansel Capital
(720) 288-8495

benhansel@yahoo.com
 



Kraig Biocraft Laboratories Announces New Interview With CEO


January 19, 2012
Source:
http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-new-ceo-interview-otcqb-kblb-1608535.htm



Kraig Biocraft Laboratories Featured In Current Issue Of Textile World

LANSING, MI -- (Marketwire - Feb 7, 2012) - Kraig Biocraft Laboratories, Inc.(OTCQB: KBLB) (PINKSHEETS: KBLB) announces that the Company's spider silk technologies, including Monster Silk, are featured as the "Quality Fabric of the Month" in the current issue of the leading textile industry publication Textile World.

An electronic version of the Textile World article Spider Silk: Potential Unleashed is available online at the following link, http://ctt.marketwire.com/?release=848923&id=1236700&type=1&url=http%3a%2f%2fwww.textileworld.com%2fArticles%2f2012%2fJanuary%2fJan-Feb_issue%2fDepartments%2fQFOM_Spider_Silk.html

We are honored to be featured in the current issue of Textile World as the "Quality Fabric of The Month", stated Company Founder and CEO, Kim Thompson.  "This recognition of our achievements and our products by this leading industry publication just at the time when we are moving to commercialize our Monster Silk product could not have been more timely.  I want to say thank you to the people at Textile World.  For many executives in the textile industry this article will be their first glimpse of how our Company's scientific breakthroughs are making recombinant spider silk a viable, unique and exciting reality." 

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories, Inc. (KBLB)  (www.KraigLabs.com) is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of jurisdiction. 

Contact Information:
Ben Hansel
Hansel Capital
(720) 288-8495
benhansel@yahoo.com




Kraig Biocraft Laboratories to Hold Conference Call to Discuss Commercialization and Laboratory Highlights
Feb 28, 2012
Source:http://globenewswire.com/news-release/2012/02/28/469326/247456/en/Kraig-Biocraft-Laboratories-to-Host-Conference-Call-to-Discuss-Commercialization-and-Laboratory-Highlights.html 




Kraig Biocraft Laboratories to Host a Shareholder Conference Call Later Today
Comany Founder and CEO, Kim Thompson, to Discuss Commercialization and Laboratory Developments

March 30, 2012
Source: http://globenewswire.com/news-release/2012/03/30/472061/250707/en/Kraig-Biocraft-Laboratories-to-Host-a-Shareholder-Conference-Call-Later-Today.html





Kraig Biocraft Laboratories Announces New Laboratory Opening During Shareholder Conference Call
Company to move into New State of the Art Research Facility

April, 3 2012
Source:http://globenewswire.com/news-release/2012/04/03/472374/251068/en/Kraig-Biocraft-Laboratories-Announces-New-Laboratory-Opening-during-Shareholder-Conference-Call.html





Kraig Biocraft Laboratories Increases Zinc Finger Micro-Insertion Rate With Thousands of Targeted Genetic Insertions
Genetic Engineers Complete Five Separate Rounds of Zinc Finger Nuclease Assisted Genetic Insertions Over the Past Two Weeks

April 10, 2012
Source: http://globenewswire.com/news-release/2012/04/10/472794/251557/en/Kraig-Biocraft-Laboratories-Increases-Zinc-Finger-Micro-Insertion-Rate-With-Thousands-of-Targeted-Genetic-Insertions.html




Kraig Biocraft Laboratories is a 2012 Techtextil North America Exhibitor

LANSING, Mich., April 25, 2012 (GlobeNewswire via COMTEX) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB.PK) (the "Company") announces that the Company is an exhibitor at the Techtextil North America, held April 24-26, 2012 at the Georgia World Congress Center, Atlanta, Georgia.

This the 9th edition of Techtextil North America, North America's only dedicated show for technical textiles and nonwovens. The convention features an exhibit hall, with the Company in booth #1353, and it will serve as a means for the Company to promote its Monster Silk(TM) technology to governmental and corporate members of the textile industry.

"We targeted this year's Techtextil North America, months ago, as an important venue to mass market our Monster Silk technology, in person, and I look forward to highlighting the wide spectrum opportunity that this transgenic technology represents to certain convention attendees," said Company CEO, Kim Thomspon.

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories, Inc. (KBLB)  (
www.KraigLabs.com) is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's
financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of jurisdiction. 


Contact:
Ben Hansel
Hansel Capital
(720) 288-8495

benhansel@yahoo.com




Kraig Biocraft Laboratories' Monster Silkworms Pleased the Crowds at 2012 Techtextil North America


Company's Attendance Generates Additional Spider Silk Interest at North America's Only Dedicated Show for Technical Textiles and Nonwovens

May 1, 2012
Source:http://globenewswire.com/news-release/2012/05/01/474964/254046/en/Kraig-Biocraft-Laboratories-Monster-Silkworms-Pleased-the-Crowds-at-2012-Techtextil-North-America.html



 
Kraig Biocraft Laboratories Increases Monster Silk(TM) Silkworm Yields at the Company's New Laboratory
Increase in Transgenic Silkworm Production Seen as Major Step Toward Commercialization of Monster Silk(TM)

LANSING, Mich., June 27, 2012 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB.PK) (the "Company" or "Kraig") announces that the Company's recently opened private laboratory has significantly increased Kraig's ability to generate its proprietary Monster Silk(tm) production platform silkworms.

The initial focus of the Company's facility is to assist in the commercialization of Kraig's product, Monster Silk(tm), by significantly ramping up production of the Company's proprietary transgenic silkworms that produce Monster Silk(tm), a new recombinant spider silk based fiber with potentially broad applications for consumers and industry in the multi-billion dollar marketplace for textiles and performance polymers.

"Our main goal, for the Company's recently opened laboratory, was to rapidly increase our ability to raise our Monster Silk(tm) silkworms. In the short time it's been operational, we have effectively quadrupled our ability to produce transgenic silworms, which produce Monster Silk(tm),"said Company founder and CEO, Kim Thompson.

"We knew that the increase in our laboratory production would be fundamental to the commercialization of Monster SIlk(tm)," continued Thompson.  "Now that the new laboratory is working as planned, we are looking to exponentially expand our production of Monster Silk(tm)."

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories, Inc. (KBLB)  (
www.KraigLabs.com) is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's
financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of jurisdiction. 


Contact:
Ben Hansel
Hansel Capital
(720) 288-8495

benhansel@yahoo.com




Kim Thompson Posts Letter to the Shareholders on the Kraig Biocraft Laboratories Website


Aug. 6, 2012
Source: http://www.kraiglabs.com/press-releases/letter%208%205%202012.htm




Kim Thompsons' Letter to Shareholders:
 

August 5, 2012

Dear fellow Kraig Biocraft Laboratories shareholders,

I am writing to update you on the significant progress the Company has made in executing its business plan in 2012, and to share with you our vision of the road ahead. The Company has achieved a number of milestones in late 2011 and during the first two quarters of 2012, starting with the publication of our work on the creation of spider silk based polymers by the Proceedings of the National Academy of Sciences. That was closely followed-up by Textile World, the prestigious industry publication, featuring our spider silk based polymer, Monster Silk™, as its "technical textile of the month".

The aforementioned publications, as well as many other articles, were important catalysts that focused the spotlight on our work. Following which a number of companies approached us wanting to know if our spider silk based fibers would work in their existing product lines, or to explore the possibility of using our Monster Silk™ to enter into new markets. As discussions with these companies about the potential opportunities progressed, we decided that the best approach to commercializing our Monster Silk™ would be to work cooperatively and collaboratively, possibly on an exclusive basis, with one or two companies with existing market share in our target markets. We currently define those target markets as: military, police and DHS related applications; sportswear; other industrial and consumer applications, clothing and fashion wear; and finally, existing silk product markets.

Initially, our strategy was geared toward identifying potential Monster Silk™ commercialization partners and we've been in discussions with a number of interested companies about incorporating Monster Silk™ into their products. We then exhibited to the technical textile industry at the TechTextil trade show in late April, where Monster Silk™ sparked tremendous interest at the show.

Even though the exhibition exceeded our expectations in terms of the generation of interest and numerous contacts with new potential commercialization partners, which resulted in ongoing negotiations, some may have interpreted the lack of public comment by the Company as an indication that we stopped moving our business plan forward. Nothing could be further from the truth, as we are actually accelerating on all fronts.

The nature of the negotiations we've entered into require extreme discretion due to non-disclosure and confidentiality agreements. While we cannot comment about specific discussions, I can state my personal belief, which is that the first commercial Monster Silk™ agreements will be with military and sportswear producers.

I believe that we are currently on track to enter into memorandums of understanding and letters of intent in the near term, although we continue to receive additional inquiries and we're even in the midst of the negotiating another non-disclosure agreement as I write this letter. We are likely to select one or two defense contractors (or companies that supply defense contractors) and one or two sportswear companies, to receive some degree of partial exclusivity for the commercial development of Monster Silk™ in their respective markets.

We have a once-in-a-lifetime technology. We have taken the first two quarters of 2012 to lay the foundation of our commercialization strategy to ensure that the commercialization agreements we enter into maximize long-term shareholder value. Some of the companies that we've been talking with include household names and well-known brands.

The current negotiations approach is not unlike our bold move to secure the use of zinc finger nuclease (ZFN) technology. Although the ZFN technology negotiations with Sigma-Aldrich took time, they yielded impressive results. Because of these actions and others like it, Kraig Biocraft Laboratories was able to accelerate research and development and is now positioned for greater success.

As those of you who closely follow the Company know, we have been working with Sigma -Aldrich's ZFN technology to increase the power of our own technology. In the first half of this year we experimented with the combination of our technology with ZFN. The ZFN has proven to be so powerful that it requires an adjustment in our genetic packets. Our analysis of the data has given us increased confidence that we are on the right track for the development of fibers that are even more advanced than Monster Silk™. While that work is continuing we are also in the later stages of producing more exciting new genetic configurations for use in combination with ZFN.

Until recently all of the Company's laboratory work took place entirely within university laboratories, pursuant to collaborative research agreements, which we renewed with the University of Notre Dame. Even though we increased our financing of the collaborative research project and we are now accelerating our research at Notre Dame, in the second quarter we signed a lease for a laboratory near the university. That was a big step forward in our growth and indicates our commitment to accelerate the development of new spider silk based fibers; because we believe that we are closer to the development of our pure spider silk platform. Our new private laboratory at Innovation Park, a state of the art facility near Notre Dame, is equipped with top of the line security, including bio-sensors, which we feel is more appropriate for our technology at its current state of development.

Kraig Biocraft Laboratories has made great strides and achieved several milestones in the first two and a half quarters of 2012, plus we laid down a very solid foundation for both our commercialization program and for advanced R&D. Laying down that foundation has been grueling work, but, now that the foundation is in place, the next stages of development should be more exciting and tangible.

Our plan is to continue to build on our research knowledge to develop more advanced polymers in the near term. On the Monster Silk™ commercialization front, we are currently in privileged discussions with potential commercialization partners including some medium sized and larger companies. We anticipate that those discussions will bear fruit in the near term.

In short, I am determined to unlock the maximum value for our shareholders. We are delighted with the current positioning of our commercialization opportunities, which we're building on the foundation we laid out in the first half of the year in order to seize those opportunities. I know that this comprehensive approach takes more time, but I'm convinced that we control our own destiny and this will enable us to create far more long-term shareholder value.

Thank you for supporting the Company and taking the time to read this letter. I am very proud of our innovative Company and the ingenious technology we've developed, but I am more confident than ever that Kraig is favorably positioned to become a leading technical materials firm and I am even more intensely excited about the big future that lies ahead for Kraig Biocraft Laboratories.

Sincerely,

Kim Thompson, CEO



 Forward-looking statements:

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.




Kraig Biocraft Laboratories Announces the Creation of New Recombinant Spider Silks


The New Spider Silks, Which Have an Unusual Red Cast and Were Designed for Superior Strength Are Collectively Designated by the Company as "Big Red"

LANSING, Mich., Jan. 14, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig") announced that researchers, working pursuant to Kraig's collaborative research program, utilizing customized spider silk genetic engineering sequences, succeeded in creating a new type of recombinant spider silk, which the Company is designating as "Big Red."

The "Big Red" silk is currently being spun within the laboratory by transgenicly modified silkworms.

"'Big Red' is a composite fiber," said Company CEO, Kim Thompson. "This new type of fiber was designed to be a combination of spider silk proteins, silkworm silk proteins and protein from an unrelated species. From a genetic perspective, what significantly differentiates this material from our Monster Silk™ is the unique spider silk genetic sequence that we used, which we designed to increase strength to weight ratios. Another important difference is the incorporation of a unique protein, which gives the new fiber its designation as 'red.' 

"The design for 'Big Red' derived from what we learned about the mechanical characteristics of recombinant spider silk fibers from our work with Monster Silk™," continued Thompson. "Specifically, the new fiber was designed to place more emphasis on tensile strength and slightly less emphasis on elongation. We anticipate that 'Big Red' will be a powerful arrow in our quiver as we move to commercialize Monster Silk™ and the Company is hopeful that this new material will follow it in the commercialization pipeline. In my view, the creation of Big Red demonstrates the power of our technology to continue to develop new and exciting materials."

The "Big Red" name comes in part from the fact that the fibers have a slight red cast. Under UV light, the new fibers actually glow bright red.

Thompson further stated, "The successful creation of these new materials once again validates our scientific models. Based upon the observed levels of color expression and the nature of the spider silk genetic configurations used in its creation, the hope is that it will find its own significant niche in the technical textiles marketplace. Preparation for mechanical testing of the new fiber is currently taking place."

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.





Kraig Biocraft Laboratories to Launch Monster Silk(TM) Pilot Production Program


LANSING, Mich., Jan. 22, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig") announced today that it plans on launching its pilot production program for Monster Silk™, the Company's recombinant spider silk, in the first or second quarter of 2013.

The program is designed to transition Kraig from laboratory scale production to commercial. scale production of Monster Silk™. The Company anticipates launching the pilot program within the next sixty to ninety days. The initial goals for the pilot production program are to confirm production scalability and cost structures for Monster Silk™, as well as to satisfy the demand for larger scale Monster Silk™ sample requests from textile producers and product developers.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

CONTACT:
Ben Hansel
Hansel Capital, LLC.
(720) 288-8495
benhansel@yahoo.com




Kraig Biocraft Laboratories' Recombinant Spider Silk Product Development Receives Coverage From Prestigious Textile Trade Publication WTiN


 LANSING, Mich., Jan. 28, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig") announced today that World Textile Information Network ("WTiN") recently published an article, entitled "Commercializing the science of spider silk", featuring the Company and its genetically engineered spider silk technologies.

As the WTiN article states, "Kraig Biocraft Laboratories has experienced growing success developing its recombinant spider silk in the last two years." The article describes Kraig's product development and includes the first published photos of the Company's new composite spider silk fiber, "Big Red." The new genetically engineered spider silk fiber takes its name from the fact that it glows bright red under UV illumination. Additional photos of what the Company hopes to be a breakthrough material will be posted on Kraig's website.

The WTiN article is available at the following link: http://ei.wtin.com/article/fQowSDlzdX2/2013/01/24/commercialising_the_science_of_spider_silk/

World Textile Information Network, established more than 100 years ago and based in the UK, is the world's leading textile news and information provider, with unrivalled textile expertise. "WTiN Intelligence" is part of the WTiN, whose magazines include- Textile Month International, Knitting International, Future Materials, Nonwovens Report International, Digital Textile, Twist and International Dyer, as well as newspapers at many of the world's leading textile exhibitions.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

 CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495




Kraig Biocraft Laboratories' Monster Silk(TM) Pilot Production Program Enters Second Stage Ahead of Schedule


Company Accelerates Recombinant Spider Silk Pilot Production After Hitting Target Objectives
LANSING, Mich., Feb. 4, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (KBLB) (the "Company" or "Kraig") announced today that it is accelerating its pilot production program, as a result of positive initial data from the first stage of the trial.

The acceleration to the second phase of the program is designed to increase production capacity of Monster Silk™, the Company's recombinant spider silk, by more than tenfold over the first stage. Kraig's strategy calls on further accelerating the production program by initiating a third stage, if the program continues to meet its targets.

The first phase of the pilot production program for Monster Silk™ is continuing, even as phase two is being launched. The purpose of the program is to verify scalability and favorable production economics of Monster Silk™, to significantly increase production, and to form the basis of large scale commercial production of the Company's recombinant spider silks.

"The initial success of the first stage has given us the confidence to accelerate the program," said Kraig founder and CEO, Kim Thompson. "We are now well ahead of the schedule that we envisioned even a few weeks ago. This is a critical step forward in the commercializing of our laboratory discoveries. The launching of stage two, which I view as the heart of the pilot production program, is the most exciting and momentous event in the Company's history, second only to our invention of Monster Silk™."

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

CONTACT: Ben Hansel, Hansel Capital, LLC. 

(720) 288-8495

benhansel@yahoo.com




Kraig Biocraft Laboratories and SSM Industries Sign Memorandum of Understanding to Jointly Commercialize Recombinant Spider Silk


LANSING, MI, Feb 13, 2013 (GLOBE NEWSWIRE via COMTEX) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig") and SSM Industries, Inc. ("SSM") jointly announced today that they have signed a memorandum of understanding ("MOU") to jointly commercialize Kraig's Monster Silk(TM) recombinant spider silk.

The purpose of the MOU is to develop a framework for cooperation between SSM and Kraig regarding spider silk commercialization and marketing. The parties anticipate collaborating to develop knitted and woven textiles utilizing Monster Silk(TM) and possibly other recombinant spider silks, which have been developed by Kraig or which are in its development pipeline.

The collaborative work would extend to product applications' development and marketing. Under the MOU the two companies would jointly develop select applications, for Monster Silk(TM) and other recombinant spider silks which have been developed by Kraig. This alliance is intended to support the market development for spider silk based textiles.

"SSM Industries, Inc. is an American company with a proven track record of innovation and excellence in technical textiles and protective apparel, so we are delighted to be working with them," said Kraig CEO and founder, Kim Thompson. "Today's memorandum of understanding allows us to work toward combining the capabilities of both companies in pursuing markets for knitted and woven applications of spider silk.

"This MOU is a big step forward in moving our spider silk products from the laboratory and toward meeting the increasing demand for innovative high strength materials, technical textiles and protective composites. I believe that it greatly accelerates Kraig's access to critical protective clothing and technical markets.

"This collaboration with a technical textile innovator marks a major milestone toward bringing Kraig Biocraft Laboratories' genetically engineered spider silks to mainstream markets in commercial volume," concluded Thompson.

"We are very happy to enter into co-operation between Kraig Labs and SSM Industries for developing the markets and product applications for spider silks, especially in regard to life & limb protective gear, apparel and composites," said SSM spokesman Phil Chandler.

"Both parties acknowledge the potential of working together to develop and promote recombinant spider silk related textiles and product applications," continued Mr. Chandler. "I believe the signing of the MOU between our companies marks a starting point for the development of significant markets for spider silk technologies. We are excited to be at the ground floor as we work together with Kraig to develop and grow this market segment. This new relationship demonstrates SSM Industries commitment to unlocking markets and developing innovative solutions that benefit our world and satisfy global demand."

The parties caution that while the MOU is a major step toward a binding agreement, it should not be relied upon as a guarantee that a binding agreement will be completed.

Kraig Biocraft Laboratories is in discussions with other companies to complete a consortium to drive the penetration of its recombinant spider silks into global markets.

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories, Inc. ( www.KraigLabs.com ) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

About SSM Industries

SSM Industries Inc. ( www.Ssmind.com ), based in Spring City, TN, is a full service safety and protective fabric manufacturer that manufactures flame resistant, cut resistant, and thermal fabrics.

SSM has established itself as an innovator in technical textiles and performs in-house yarn spinning, knitting, weaving, dyeing and finishing. The company produces products that are used by the U.S. military, the auto racing industry, firefighters, first responders, and industrial applications where materials with strength and protective properties are required. Internal research and development and an in-house Military certified lab to test the finished fabrics complement SSM's vast technical textile capabilities.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495

ir@kraigabs.com


 

Kraig Biocraft Laboratories to Host Corporate Conference Call


Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Kraig" or "The Company") announces an advance conference call advisory for all shareholders and other interested parties.

LANSING, Mich., Feb. 19, 2013 (GLOBE NEWSWIRE) --

The Company plans to host a conference call for the purpose of discussing production, commercialization and scientific milestones as well as other corporate developments, featuring the Kraig's founder and CEO, Kim Thompson and is tentatively scheduled for late-March to mid-April, pending the travel schedule of Thompson and members of the scientific team.

Kraig recently announced that it signed a memorandum of understanding with SSM Industries Inc.(http://www.Ssmind.com) to jointly commercialize Kraig's Monster Silk(TM) recombinant spider silk. Other recent announcements included that the Company launched and is accelerating its Monster Silk(TM) pilot production program, as well as that it succeeded in creating "Big Red", a new type of recombinant spider silk.

The Company plans on releasing definitive details, including call-in details, time and format, at least one week prior to conference call and shareholders are invited to submit questions to http://ir@kraiglabs.com.

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

                                                                                       Ben Hansel, Hansel Capital, LLC. (720) 288-8495



Kraig Biocraft Laboratories Provides Update on the Monster Silk (TM) Pilot Production Program's Second Stage; Program is Accomplishing Its Targeted Milestones and Remains Well Ahead of Schedule
The Ongoing Pilot Production Program's Second Phase Results are Exceeding First Phase


LANSING, Mich., Feb 25, 2013 (GLOBE NEWSWIRE via COMTEX) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig"), the leading developer of advanced spider silk based fiber technologies, announced today that the first two stages of its Monster Silk(TM) pilot production program ("program") are running ahead of schedule and that both stages of the program are on track to meet or exceed the program's goals.

The production capacity for the first two stages exceeds the Company's prior maximum capacities by a factor of four or five.

The program is designed to be the basis of the Company's large scale commercial production of its recombinant spider silks. The program is designed to run in three stages; with each successive stage launching when the previous stage's data indicates that the program is reaching, or exceeding, its benchmarks.

The current data supports the continued fast-tracking of the program, as the second phase is developing on track, surpassing the trial's initial phase in terms of capacity and success rates. The first stage continues to run ahead of expectations and is already moving to an advanced state.

"So far the pilot production program has exceeded our expectations and is confirming that our production model is fully scalable, as Phase II surpassed the program's first phase, despite the fact that it's a much larger trial," said Kraig founder and CEO, Kim Thompson. "From the beginning, this has been an ambitious program, which now appears to be rewarding our efforts. We are continuing to rapidly advance through stage two of the production program."

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com), a fully reporting biotechnology company, is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. The Company has recently launched a pilot production program as a major step toward large scale commercial production.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.com
 



Kraig Biocraft Laboratories Enters Third Phase of Its Monster Silk(TM) Pilot Production Program Ahead of Schedule
Phase Three Launches on the Heels of the Early Successes of Stages One and Two


LANSING, Mich., Feb 28, 2013 (GLOBE NEWSWIRE via COMTEX) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig"), the leading developer of advanced spider silk based fiber technologies, announced today the launch of stage 3 of its pilot production program ("program").

The program is designed to run in three stages, each launching in turn when the data from the previous stage indicates that the program is reaching its benchmarks.

"The launch of stage three indicates stages 1 and 2 are exceeding our expectations with hatch rates exceeding 60%. At the current rates of the program's development, we should be able to announce that hatchlings from the first round have begun spinning Monster Silk(TM) within the next few days," said Company founder and CEO, Kim K. Thompson.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495

ir@KraigLabs.com

 


Kraig Biocraft Laboratories Announces That the First Stage of Its Pilot Production Program Has Resulted in Monster Silk ™ Cocoons
Pilot Production Program is Now Producing Monster Silk ™ Cocoons


Kraig Biocraft Laboratories Announces That the First Stage of Its Pilot Production Program Has Resulted in Monster Silk(TM) Cocoons

LANSING, Mar 04, 2013 (GLOBE NEWSWIRE via COMTEX) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig"), the leading developer of advanced spider silk based fibers, announced today that the silkworm hatchlings from the first stage of its Monster Silk ™ pilot production program ("program") have now spun cocoons. The cocoons are made of Monster Sil ™, the Company's recombinant spider silk.

The program is running in three stages, with stage 1 being the first of the production stages to produce Monster Silk ™ cocoons. Stage 2 of the program is now entering a very advanced state. All three stages are ahead of schedule and are hitting or exceeding their milestones.

"Our focus on innovation and scientific excellence is transitioning well from the laboratory to production, and this ambitious pilot production program is designed to test our systems and to become the basis for large commercial scale production," said Company founder and CEO, Kim K. Thompson.

"The pilot production program goals included confirming Monster Silk's ™ production scalability; to get these results so smoothly is a tremendous boost the Company's expansion plans."

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.com
 



Kraig Biocraft Laboratories Receives Invitation From Foreign Government
Kraig Biocraft Laboratories Accepts Invitation to Explore Production Opportunities
 

LANSING, Mich., March 12, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig"), the leading developer of advanced spider silk based fibers, announced today that the Company has received an invitation from the council office of a foreign country to visit that country. The purpose of the invitation is to meet with governmental officials to discuss and explore the potential to produce the Company's recombinant spider silk there.

"It is a great honor for Kraig to receive this diplomatic invitation," said Company founder and CEO, Kim Thompson. "It also represents a unique opportunity. We have accepted the invitation to visit a potential production location and to meet with officials to discuss the business opportunities presented."

The Company's CEO anticipates traveling to that country and exploring the production possibilities within the next three weeks.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495

 

 

Kraig Biocraft Laboratories' Monster Silk(TM) Cocoons Now Being Reeled  


Spider Silk Pilot Production Program Moves to Advanced State

LANSING, Mich., March 19, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig"), the leading developer of advanced spider silk based fibers, announced today that the cocoons from the first stage of its Monster Silk™ pilot production program ("program") have been reeled into threads of the Company's recombinant spider silk as the program moves into an advanced state.

Additionally, the silkworm hatchlings from the second stage of the program have now spun cocoons that are made of Monster Silk™.

"The pilot production program has advanced well ahead of our expectations. At this rate, we will be facing some near term decisions regarding the launching of commercial production. In my opinion, we are now reaching major milestones every two to three weeks. We are undergoing tremendous developmental changes, which we believe will lead to substantial growth of our business over the next few months," said Company founder and CEO, Kim Thompson.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495


 

Kraig Biocraft Laboratories CEO and Scientific Advisory Board Member Meet With Government and Industry


Malcolm Fraser Invited to Meet With Indian Scientists, Government and Industry

LANSING, Mich., March 25, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company"), the leading developer of advanced spider silk based fibers, announced today that Dr. Malcolm Fraser, PhD, an influential member of the Company's scientific advisory board, is in India meeting with scientists, government officials and industry. The Company's CEO and Founder, Kim Thompson, is also traveling and is currently in another country meeting with government officials and businessmen to discus and explore production and processing opportunities for Monster Silk™ and other recombinant spider silks.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc (http://www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495




Kraig Biocraft Laboratories to Hold Shareholders' Meeting on April 16, 2013


Company CEO Posts Letter to Shareholders

 LANSING, Mich., April 3, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company"), the leading developer of advanced spider silk based fibers, will hold a shareholder meeting on April 16, 2013. Along with the notice of meeting, the Company's founder and CEO, Kim K Thompson has posted a letter to the shareholders on the Company's website.

"We plan to continue accelerating our commercial development through 2013 and beyond," said CEO and founder Kim K Thompson. "We will also be announcing a shareholder conference call to be held sometime after the shareholders' meeting, to discuss our progress and ambitious plans for 2013 and 2014."

To view the letter to shareholders as well as the notice of the shareholder meeting along with details regarding the meeting please go to http://www.KraigLabs.com. The letter to shareholders and the notice of the shareholder meeting are also being provided to shareholders through electronic communication, for those who have previously opted for electronic communication or through the US postal service.

Furthermore, the Company is inviting shareholders to join the Kraig e-mail alert list, which will allow the Company to communicate more effectively with its shareholder community. For periodic updates, notices and important press releases, please subscribe by sending an email containing the words "shareholder, add me to the list" to http://Shareholder@KraigLabs.com.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495




Kraig Biocraft Laboratories Announces Results of 2013 Meeting of Shareholders


Attending Shareholders Unanimously Approve All Board Proposals at Meeting

 LANSING, Mich., April 17, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company"), the leading developer of advanced spider silk based fibers, announced today that all of the Board of Director's proposals were approved at its meeting of shareholders held yesterday in Lansing, Michigan.

All three amendments to Company's charter listed on the meeting agenda passed with unanimous attending shareholder approval. The amendments were designed to help management advance the business model in a more streamlined fashion.

"The overwhelming support of the attending shareholders, expressed over nearly four hours of discussions, and the unanimous vote on all of management's proposals, is a validation of our plans for production and commercialization," said CEO and founder Kim Thompson. "I am looking forward to communicating further details of our plans and progress to the shareholders in an upcoming shareholder conference call."

"I would like to thank the shareholders who were able to take time out of their busy schedules to attend the meeting," continued Thompson. "It was extremely gratifying to meet other shareholders, who share many of the same visions and goals for the Company and the technology."

A copy of the three amendments to the Company charter which were approved by the shareholders at yesterday's meeting is available on the Company's website under the notice of meeting section.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495




Kraig Biocraft Laboratories Announces Plans to Launch Initial Commercial Production of Monster Silk(TM)


The Commercial Production Program Will Build on the Successes of the Pilot Production Program, Which Was Launched Earlier This Year

 LANSING, Mich., May 7, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company"), the leading developer of advanced spider silk based fibers, today announced plans to launch its initial commercial production of Monster Silk™. The announcement of the Company's decision to launch commercial production follows the early successes of its of Monster Silk™ pilot production program. 

"We have received strong indications of interest from potential customers and potential commercialization partners," said, CEO and founder, Kim Thompson. "Many of these companies have been very patient with the fact that our laboratory production has been limited and can not satisfy their demand for quantities of material sufficient to run test weaves and end product testing.

"Moving from our pilot production program to commercial production is a very big jump, but it is also a natural progression," continued Thompson.  "We have been laying the groundwork for this expansion over the last twelve months. We are confident in the decision and we are hopeful that we can accomplish the launch during the third and fourth quarters. Our plan is to begin commercial production to meet customer needs, secure future orders and capture market share in the technical textiles market."

Kraig's pilot production program will continue to run, in order to supply continuing data and help grow the Company's production capacity.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495




Kraig Biocraft Laboratories Ends Quiet Period



LANSING, Mich., July 1, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company"), the leading developer of advanced spider silk based fibers, today announced the end of the quiet period phase related to its recently filed S1 financing registration and a second potential financing that the Company has now terminated.

"We are very happy to be able to announce the end of this quiet period, and we want to thank our shareholders for their patience," said Company CEO and founder, Kim K Thompson. "Quiet periods during times when certain financings are being prepared are a normal part of the Company's regulatory compliance obligations. While it is wonderful to receive the underlying finance, the quiet periods themselves are an unwelcome, but necessary burden. Having successfully carried that burden, we are now very happy to set it down."

During the quiet period, the Company was unable, from its perspective, to effectively disseminate corporate information announcements and public relations announcements. The Company had come to terms with a New York based investment banking firm for a potential financing (in addition to the financing described in the recently filed S1) that would have necessitated a second S1 registration. The Company has determined however that the burden of an additional quiet period, or any further open ended extension of the quiet period, would be too counterproductive. The Company is looking forward to resuming more open communications with the financial markets and shareholders.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495




Kraig Biocraft Laboratories to Add Key Personnel


Management Growth to Focus on Sales, Product Applications Development and Marketing

 LANSING, Mich., July 8, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Kraig"), the leading developer of advanced spider silk based fibers, today announced plans to add key personnel, in order to support its production growth strategy and expand its ability to service potential clients as Kraig grows.

Kraig is looking to add two talented and experienced individuals to its team, to help with a wide array of responsibilities, ranging from operations to market development.

The fundamental considerations include a balanced mix of qualifications, experience and reputation.

"We're looking for key individuals, to work as part of a cooperative team to accelerate the Company's growth in 2013 and beyond," stated Company CEO and founder, Kim K Thompson. "In addition to improving organizational effectiveness, I welcome the addition of valuable perspective and insight that these key hires may add to our organization. Frankly, as we transition from being a research and development company to the commercialization of new recombinant fibers, we need to add more hands on deck to take on the increased responsibilities. I am thrilled to be adding to our executive team to help guide our product development, sales and marketing, and technological efforts."

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495




Kraig Biocraft Laboratories to Launch Commercial Production of Monster Silk(TM)


The Commercial Production Program for Recombinant Spider Silk Slated to Begin This Summer

 LANSING, Mich., July 15, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, today announced that it is scheduled to start commercial production of Monster Silk™.

The first phase, scheduled to begin within the next three weeks, will be focused on establishing commercial scale production capacity. "We have been laying the ground work for commercial production over the last six months with our pilot production program," said Company CEO and founder, Kim K Thompson. "We have moved cautiously and prudently in testing our methods and procedures. It's now time to convert the pilot program to commercial production."

The launch of commercial production follows on the heels of the Company's pilot production program which has been running since January.

"The successful scale-up to commercial production is a significant milestone for any company," continued Thompson, "and, considering the importance we place on Monster Silk™, I have to agree that this is a momentous step for Kraig. It is especially exciting because we are creating what we believe will be the world's first commercial scale production of recombinant spider silk."

While the Company is creating this production capacity, it is in discussions with one or more other countries about further expanding and diversifying its production capacity for Monster Silk™.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (kraiglabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495




Kraig Biocraft Laboratories Launches New Website


New Website Intended to Communicate the Company's Vision and Technology

 LANSING, Mich., July 22, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, today announced the launch of its entirely new website,www.kraiglabs.com.

"Although we've worked with cutting-edge biotech companies in the past, our whole team was fascinated by the incredible things Kraig Biocraft is achieving in the labs," commented Jonathan Keim, owner of GPGSolutions . "We truly enjoyed working with the Company and being a part of its exciting story."

"As we move toward the commercialization of recombinant spider silks, it is important that we build our band and our image," said Company CEO and founder, Kim K Thompson. "With Jonathan's help, we built a website from the ground up, to better highlight the Company's high-tech foundations and enhance our public image. The new and improved website is also part of our plan to improve communication with prospective partners, customers and our shareholders. We hired GPGSolutions' because of their stellar reputation and their enthusiasm for the project. Their creativity, responsiveness and technical ability worked to produce a platform that better represents our vision and promotes our brand."

Shareholders and interested persons who have not already done so, are invited to subscribe to the Company's email updates in advance of the launch of that program. The sign in button can be found at the bottom of the Investors page of the Company website. 

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495




Kraig Biocraft Laboratories Announces Monster Silk(TM) Production at Quantities Necessary for Producing Textile Prototypes


Company to Increase Scale of Its Recombinant Spider Silk Production

 LANSING, Mich., Aug. 19, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, today announced that the Company's pilot production program has successfully produced a sufficient quantity of Monster Silk™ cocoons to allow the Company to make the first Monster Silk™ textile prototypes.

The cocoons still need to be reeled and processed into yarn before the first prototype and sample textiles can be produced. The announcement puts the Company firmly ahead of its most recent textile production schedule. The first textiles are slated for mechanical testing of the properties of recombinant spider silk in various textile knits and/or weaves.

The Company also announced today a change in its production schedule and scale of operations for its initial commercial production program. "The timing of cocoon production from the pilot program worked out well, because we were getting indications from the field that the weather developing in August was not ideal for the mulberry production needed for our commercial launch," said Company founder and CEO, Kim K. Thompson. "We are going to take advantage of the fact that with this supply of cocoons we have bought ourselves some breathing room. The Company plans to delay the launch of commercial production until sometime in September. We can now do this with no expected impact on our schedule to produce new textiles. By moving the production launch to September we may also be in a position to increase the scale of the initial commercial production by a factor of two or more. The Laboratory is taking full advantage of the time by working on egg production in order to increase the scale of the commercial launch."

"The pilot production program was the first time that we raised Monster Silk™ silkworms in real world conditions," continued Thompson. "The success of that program has enabled us to prepare for the creation of recombinant spider silk textiles and to increase the scale of our pending launch of spider silk production on a commercial scale."    

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc.(www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495


 

Kraig Biocraft Laboratories Announces Highly Favorable Testing Results for Its Big Red Spider Silk Fiber


Initial Test Results Indicate That Big Red is Even Stronger Than Monster Silk(R)

LANSING, Mich., Sept. 10, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, today announced that the Company's initial testing of its recombinant spider silk, Big Red, indicate that the Company's new recombinant fiber is stronger than Monster Silk®. The testing indicates that Big Red's strength, as measured by the ultimate load it can withstand before breaking, is approaching that of natural spider silk.

"These initial testing results appear to confirm the effectiveness of our design approach with Big Red," said Company founder and CEO, Kim K. Thompson. "Big Red was designed to be even stronger than our breakthrough product, Monster Silk®," continued Thompson. "If the follow on testing confirms these results, Big Red will be a significant breakthrough for our Company and for material science."

"So far, Big Red has met or exceeded our expectations and design parameters. Our plan is for Big Red to follow Monster Silk® in our commercialization ramp up." 

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495


 

Kraig Biocraft Laboratories Announces That Monster Silk(TM) is Stronger Than Steel


Company Confirms Some of Monster Silk's Extraordinary Qualities

LANSING, Mich., Sept. 23, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, today announced that the Company's Monster Silk™ recombinant spider silk fibers are stronger than the comparable weight of traditional structural steel.

"We've long believed that Monster Silk™ tensile strength is stronger than steel, but it's a bonus to be able to quantify and confirm some of its properties for potential commercialization partners," said Company founder and CEO, Kim K. Thompson. 

"Since the Company is producing fibers that have never been produced before, we've decided that we will expand our ability to ascertain these results. Therefore, we are investing in testing and measurement equipment that will help us to accelerate the testing of our fibers' unique qualities in a more efficient manner. We believe that this will advance our ability to communicate intelligently with our potential commercialization partners, improve the effectiveness in the laboratory, and greatly reduce the commercialization timeline for future products that we plan on bringing online."

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495





Kraig Biocraft Laboratories Launches Commercial Production of Monster Silk(TM)


The Company Plans on Producing Metric Tons of Recombinant Spider Silk in 2014

LANSING, Mich., Oct. 7, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, today announced the launching of the Company's commercial production program with the recent hatching of its first batch of Monster Silk™ silkworms for commercial production.  

Furthermore, the Company is currently expending resources to augment the scale of its Monster Silkworm™ production over the next 30 to 90 days. This move coincides with the Company's planned strategy to rapidly increase its production capacity. The Company's strategy is to commit the vast majority of its initial production capacity to a propagation program designed to increase its production population. A smaller portion of the first commercial production generation should also yield fibers which can be dedicated to the production of woven textile samples.

"Our launch of our commercial scale production of Monster Silk™ is a long awaited major milestone for Kraig, as we demonstrate our ability to convert recombinant spider silk, and Monster Silk™ most specifically, from an exciting laboratory technology to a marketable product," said, CEO and founder, Kim K. Thompson. "We believe that rolling out the world's first recombinant spider silk commercial production project will only expand our global development prospects, for Monster Silk™ and other high technology fibers." 

"It has taken many years to go from my initial concept of recombinant spider silk to the laboratory production of Monster Silk™ and now the actual launch and scaling up of the commercial scale production. I want to thank our investors and, most particularly, the research scientists, whose work and dedication has made this long anticipated day possible."

"Given the current planned production schedule, we could theoretically be producing Monster Silk™ in metric ton quantities by early January. A more conservative estimate, given the realities of launching such a ground breaking and commercially unique project, would be to reach that major milestone in mid 2014. This move reaffirms our view that Kraig is the world's leading developer of recombinant spider silk technologies," concluded Thompson.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495




Kraig Biocraft Laboratories and Warwick Mills Sign Strategic Joint Development Agreement


Joint Intellectual Property Agreement Covers the Collaborative Development of Spider Silk Based Textiles

LANSING, MI--(Marketwired - Oct 21, 2013) - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company"), the leading developer of advanced spider silk based fibers, and Warwick Mills, Inc. ("Warwick"), a leader in the engineering and development of advanced technical textiles and other protective materials, jointly announced today that they have signed a collaborative development agreement concerning the development and commercialization of advanced textiles utilizing Kraig's Monster Silk™ recombinant spider silk technology.

Under terms of the agreement, the two companies will jointly develop innovative textile products based on Kraig's Monster Silk™ fibers. Under the terms of the agreement, the two companies will jointly own textile product related intellectual property which is developed as a result of the collaboration. 

Joint development will initially focus on Monster Silk™ weaving, testing and near term applications. The companies believe that this collaborative relationship will help expedite the commercialization of Monster Silk™ and future spider silk based technical fibers.

"This collaborative undertaking represents a huge step forward in our commercialization efforts. The pairing of Kraig's spider silk technology with Warwick's world-class technical textiles applications engineering and weaving abilities is a bold move which we believe will enhance and accelerate the penetration of spider silk into technical textile markets," said Kraig CEO and founder, Kim K. Thompson.

"Warwick Mills is recognized for engineering technical textiles with protective applications and its ability to bridge the gaps between innovative technologies and market integration. Their global reputation is built on the foundation of innovation and performance. I believe the joint development agreement is an important milestone and that Warwick's impressive capabilities makes them an ideal bridge builder between Kraig's expertise in spider silk technologies and the capturing of market share in the technical textiles arena," concluded Thompson.

"Warwick is looking forward to developing new textiles in cooperation with Kraig Biocraft Laboratories, and its Monster Silk™ technology. Spider silk fibers are a powerful new technological approach to potentially opening up new application and markets," stated Charles Howland, President of Warwick.

"The future of textiles will continue to be driven by innovation and we believe that our textile engineering capabilities and Kraig's fibers can change the game in some important applications. These technologies could potentially result in higher performance textiles which would enable very advanced safety and military equipment. This collaborative agreement is a big step forward in the development of exciting new textiles with potential applications for the technical textiles and protective textiles marketplace," concluded Howland.

About Warwick Mills

For the past century, Warwick Mills (http://www.warwickmills.com) has been a leader in the engineering of technical textiles for protective applications. Warwick develops and integrates complex fiber composites for the most challenging safety applications. Its cooperative development strategy relies on its core technologies in technical textiles, custom adhesives, and performance coatings, from research and development to testing and full-scale manufacturing. This strategy ensures customer confidence for every challenge.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.




Kraig Biocraft Laboratories Announces New Independent Registered Accounting Firm.


 LANSING, Mich., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, announced today that it has appointed M&K CPAs ("M&K") as the Company's new independent registered public accounting firm and has thereby dismissed PS Stephenson & Co, P.C. ("Stephenson") from that role. The decision to engage M&K was made by the Company's audit committee, acting on behalf of the Company's board of directors, on October 28, 2013.

"As a result of the Company's changing needs, as it advances toward commercialization of recombinant fibers, and after consulting with our Stephenson representative, we determined that it would be best to engage a new, larger accounting firm that is positioned to address our future needs. Therefore, we are very pleased to engage M&K as our independent auditors."

"We appreciate Stephenson's expert service, which they've proficiently provided for the past two years, and we would like to thank them for their professionalism," said Kraig CEO and founder, Kim K. Thompson.

The Company had no unresolved disagreements with Stephenson, during the two most recent fiscal years and through the date of this release, on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure. The move to M&K as the Company's registered accounting firm was made in consideration of M&K's considerable expertise and the Company's changing needs as it moves toward commercialization.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495

 


 Kraig Biocraft Laboratories Delivers First Shipment of Monster Silk to Warwick Mills


 LANSING, Mich., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, announced today that the Company delivered the first shipment of its Monster Silk(TM) recombinant spider silk fiber to Warwick Mills, Inc. ("Warwick"). Warwick is a leader in the engineering and development of advanced technical textiles and protective materials.

The shipment represents a key step in the Companies' collaborative development initiative with Warwick, which will target the development of advanced spider silk based textiles.

"This first shipment of Monster Silk(TM) marks a new phase for Kraig and it demonstrates the efficacy of our research and development program and business model," said Kraig CEO and founder, Kim K. Thompson. "Warwick Mills is an innovator with a strong track record of developing and weaving advanced high strength textiles. So the delivery of this first small shipment of recombinant spider silk to them is a very exciting milestone in the commercialization of spider silk," concluded Thompson.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.




Kraig Biocraft Laboratories Confirms Reports in Vietnamese Media That the Company's CEO is Meeting With High Ranking Government Officials


Kraig is in Advanced Discussions Regarding the Establishment of Advanced Fiber Production in Vietnam

DALAT, Vietnam, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, announced today that the Company has been meeting with high level Vietnamese government officials, regarding the establishment of advanced fiber production in Vietnam. Reports of these meetings have been receiving wide coverage in Vietnamese press and television.

An example of the Vietnamese coverage can be found at the following link:

http://vovworld.vn/en-US/News/Kraig-Biocraft-Laboratories-CEO-welcomed-in-Hanoi/207937.vov

"Vietnam is a nation with a wealth of infrastructure and experience in raw silk fiber production," said Company CEO and Founder, Kim K. Thompson. "We believe there is a natural fit between our desire to achieve large scale commercial production and Vietnam's desire to modernize its industry and increase productivity," continued Thompson.

"We are very excited about the possibility of working with Vietnam. Our discussions regarding commercial production have been very productive. We have been very well received and our hosts have been very gracious. I would like to thank the parties who have taken the time to help make this trip as fruitful as possible. I am very impressed with what I've seen in Vietnam, including their passion for sericulture," Thompson concluded.

The Company's CEO will continue a thorough evaluation and assessment process in Vietnam, before returning to the United States.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security

Picture of Kim With Deputy Prime Minister Vu Van Ninh on 1/8/2014


         
photos sourced from:http://vietnamnews.vn/politics-laws/249936/deputy-pm-welcomes-us-company-ceo.html





Kraig Biocraft Laboratories' Investigatory Team Reports Successful Discussions With the Government of Vietnam


Company's CEO Announces Positive Assessment of Commercial Production Potential for Monster Silk™ in Traditional Silk Producing Region

LANSING, MI--(Marketwired - Feb 6, 2014) - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company"), the leading developer of advanced spider silk based fibers, announced today some of the Company's findings from a very successful mission to assess the potential to establish commercial production of the Company's high technology silk fibers in Vietnam. Kim K. Thompson, the Company CEO and Founder, conducted meetings with high ranking Vietnamese officials, including, most notably, Deputy Prime Minister Vu Van Ninh, which was featured on Vietnam Television (VTV) National News and can be viewed at the following link:http://www.youtube.com/watch?v=fvZUqd5veZY.

"The main purpose of the trip was to investigate and discuss the possibility of establishing commercial scale production of Monster Silk™ in Vietnam," said Thompson. "We inspected silk production locations and infrastructure, potential vendor supply chains and sourcing operations, as well as the scope and depth of the country's sericulture industry. The trip confirmed that Vietnam has the qualities and infrastructure needed to sustain large scale production of advanced silk fibers. We believe that our technology has the potential to revitalize the silk industry."

After meeting with DPM Ninh, Thompson's delegation was accompanied by Vietnamese diplomats on a working visit to Lam Dong province. In Lam Dong, Thompson met with high ranking officials of the provincial government to discuss potential commercial production. 

"Our discussions were very detailed and ranged from technology, land use and building occupation, to employment considerations and import/export duties. I'm very encouraged by what we have seen and by the openness and forward thinking of our Vietnamese hosts. I believe that the Vietnamese see the tremendous potential for growth and mutual benefit. Excellent progress was made on every key issue. We are now conducting a deeper evaluation of the data, and look forward to the real possibility of launching commercial scale production of high technology fibers in South East Asia," Thompson concluded.

About Kraig Biocraft Laboratories, Inc..

Kraig Biocraft Laboratories, Inc. (http://www.kraiglabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel,
Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com





Kraig Biocraft Laboratories' Spider Silk is on Track for Large Scale Production


Scientific Evaluation Team Encouraged by Monster Silk(TM) Ramp Up  Program

LANSING, Mich., March 20, 2014 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, today announced that its scientific evaluation team performed an onsite assessment and evaluation, at the request of the Company, of its genetically engineered recombinant spider silk, Monster Silk™, production ramp up. This production ramp up follows closely on the heels of the Company's successful pilot production program, which finished in late 2013. The scientific evaluation team reported that the ramp up program is on track for large scale production of Monster Silk™. The team's report also included specific recommendations for accelerating commercial scale production and for completing the transition from pilot production to commercial scale production.

"The scientific evaluation team's findings reinforce our belief that this important program is working and warrants that we commit additional resources to our scale up of Monster Silk™ production. This evaluation encourages us that we are on the right track to achieve our goal of large scale production. More importantly, the team found areas where we can improve our production efficiency in order to reach that goal. We have already started to put these plans in place to strengthen the Monster Silk™ production program," said Company Founder and CEO, Kim K. Thompson.

The goal of this program is to produce Monster Silk™ in metric ton quantities.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

- See more at: http://globenewswire.com/news-release/2014/03/20/619817/10073379/en/Kraig-Biocraft-Laboratories-Spider-Silk-is-on-Track-for-Large-Scale-Production.html#sthash.adlhG9z9.dpuf

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel,
Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com





Kraig Biocraft Laboratories' Spider Silk Production Efficiency Doubles


Monster Silk(TM) Production Surprises Company by Hitting New Milestone


LANSING, Mich., March 24, 2014 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, announced today that its genetically engineered spider silk, Monster Silk™, production program has more than doubled in productivity.

During the pilot production program, the yield rate of viable silk cocoons was approximately 30%. At those rates, the cost structure warranted the conversion of the pilot test program to a much larger scale.

The latest reports from the current production ramp up point to a dramatic and unexpected increase in yield to 70%; more than double the output efficiency shown during the pilot phase.

The initial assessment from the Company's scientific team is that the Monster Silkworms™ are acclimating to the production environment.

"This dramatic boost in productivity was a surprise to us. Our plan was to methodically increase productivity rates over the next 18 months. Our team had drawn up plans that included selective breeding and cross breeding to achieve those goals. To see such a remarkable gain in so short a time was beyond our expectations. The obvious benefits, should these rates continue, would include reduced production costs and reduced ramp up time," said Company Founder and CEO, Kim K. Thompson.

"With this doubling in efficiency, we need to focus on emplacing the necessary infrastructure to support the increased productivity. As far as challenges go, these are good problems to have.   We have already taken action to beef up our production infrastructure to support these larger numbers. The improvement in performance is dramatic; but, with such significant advancements I am cautious until I see that results are consistent over the next few months," Thompson concluded.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

- See more at: http://globenewswire.com/news-release/2014/03/24/620605/10073655/en/Kraig-Biocraft-Laboratories-Spider-Silk-Production-Efficiency-Doubles.html#sthash.NgfiCFfR.dpuf

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel,
Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com





 Kraig Biocraft Laboratories is Testing Its Big Red(TM) Genetically Engineered Spider Silk


LANSING, Mich., April 22, 2014 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, today announced that the Company received its fiber testing equipment, including customized components, to test its latest genetically engineered prototype fiber, Big Red™.

The Company announced that it created Big Red™, a new genetically engineered silk fiber, last fall, by using spider silk gene sequences. Preliminary testing indicated that Big Red™ might have properties of strength and flexibility that could have potential commercial applications.

The Company ordered testing equipment to verify the preliminary results and, after taking delivery, had the equipment customized to account for the unique nature of recombinant spider silk based fibers. 

"We are excited to perform a more rigorous evaluation of Big Red™ spider silk with the new equipment. We are hopeful of having definitive test results within the next several weeks. So far, we are seeing a lot of variability, which may be an indication of genetic variation within the transgenic colony. Not only will these tests provide us the first comprehensive set of data concerning Big Red™, and potentially guide us in improving that transgenic, but it's also the first major assessment of the new equipment," said Company founder and CEO, Kim Thompson.

The Company intends to use the testing equipment to increase the laboratory's research and development effectiveness by providing researchers with more rapid feedback on the results of their work. The ability to quickly gather and analyze data is expected to greatly improve the effectiveness of the Company's ongoing work in artificial selection of various strains of transgenic silkworms and potentially reduce the commercialization timeline for future fibers.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com), a fully reporting biotechnology company, is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. Cautionary Statement Regarding Forward Looking Information Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security..

- See more at: http://globenewswire.com/news-release/2014/04/22/628461/10077597/en/Kraig-Biocraft-Laboratories-is-Testing-Its-Big-Red-TM-Genetically-Engineered-Spider-Silk.html#sthash.qRlQu719.dpuf

CONTACT: Ben Hansel,
Hansel Capital, LLC..
(720) 288-8495
ir@KraigLabs.com





Kraig Biocraft Laboratories Launches New Investor Relations Website


Some Corporate Updates to be Delivered, in Parallel, Via Social Media

LANSING, Mich., April 28, 2014 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, today invites shareholders, and other followers of the Company's developments, to visit the new Kraig investor relations website at http://www.kblbinvestors.com#sthash.3w4IEb0C.dpuf . The Company is also announcing the launch of social media pages at Facebook and Twitter. The Company may add additional pages at other sites.

 

"Kraig has been a true trailblazer in applied biotechnology. As we've concentrated on making discoveries in the laboratory, we've held off from establishing a social media presence and avoided prematurely incorporating many other public relations tools. As the Company moves towards commercialization, we've achieved a stage in our growth where we can benefit from improved communications. We need to inform industry about what we've accomplished, both in the laboratory and in executing our recombinant spider silk commercialization plan," said Company Founder and CEO, Kim K. Thompson.

"Kraig's shareholders are one of the keys to our success and these tools should help us keep them informed. Some of the website content will be designed specifically with our shareholders in mind.

"We view ourselves as the world leader in our exciting field of biotechnology innovation. As such, we are sensitive to the competitive environment surrounding our inventions and laboratory discoveries. We will remain guarded on certain details that could give aid to potential competitors, but, as we advance our business model, we plan on revealing additional information in upcoming Company press releases," Thompson concluded.

The Company intends to distribute information on these sites in compliance with Securities and Exchange Commission's Regulation Fair Disclosure. For further Regulation FD information, please go to:http://www.sec.gov/News/PressRelease/Detail/PressRelease/1365171513574#.UxdPrc7WBxA.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com), a fully reporting biotechnology company, is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. Cautionary Statement Regarding Forward Looking Information Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

 -See more at: http://globenewswire.com/news-release/2014/04/28/630375/10078451/en/Kraig-Biocraft-Laboratories-Launches-New-Investor-Relations-Website.html?parent=632873#sthash.3w4IEb0C.dpuf

CONTACT: Ben Hansel,
Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com


 

Kraig Biocraft Laboratories' Prepares for First Monster Silk(TM) Textiles



LANSING, Mich., May 5, 2014 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Kraig"), the leading developer of advanced spider silk based fibers, announced today that Warwick Mills, Inc. ("Warwick"), a leader in the engineering and development of advanced technical textiles and protective materials, is preparing to weave the first textiles with Kraig's Monster Silk™ recombinant spider silk. This is part of Kraig's collaborative development initiative of advanced spider silk based textiles.

Kraig previously shipped Monster Silk™ yarn to Warwick, which after studying the material, requested that it be processed to additional specifications. The material was shipped back to Kraig and then studied by a silk spinning expert who analyzed the fibers. The fibers were then processed according to the directions and specifications of the spinning expert. Recently, Kraig received the reprocessed Monster Silk™ and shipped the material to Warwick. Warwick is now testing and analyzing Kraig's Monster Silk™ recombinant spider silk and determining the best ply and cord twisting for yarn optimization in preparation for creating sample textiles.

"We appreciate and respect the fact that Warwick asked us to reprocess the material instead of just moving forward at full speed with weaving or knitting," said Kraig CEO and founder, Kim Thompson. "Warwick has taken the time to do this right. As a result, the development of Monster Silk™ based textiles is at an exciting stage, Warwick is preparing to create the first Monster Silk™ textiles."

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. Cautionary Statement Regarding Forward Looking Information Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel,
Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com





Kraig Biocraft Laboratories' Spider Silk Production Poised to Double



Evaluation Team Reports Monster Silk (TM) Production Ramp Up is Succeeding

 LANSING, Mich., May 29, 2014 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, announced that its production evaluation team reported that the Company's genetically engineered spider silk, Monster Silk™, production program is thriving and is successfully accommodating a recent significant increase in the scale of production.

The Company previously reported that its pilot production program's viable silk cocoon yield rate was at approximately 30%, in late 2013. By March, after launching the commercial production ramp up program, the yields increased to approximately 70%; more than double the output efficiency from the pilot phase.   The latest report is that with the increased scale of operations in May, the high yields appear to be holding, and possibly improving even further.

The Company believes that the high yield is a result of a combination of improved production procedures and adaptability. The Company is ordering a further doubling of production in June.

"We always believed that our scientific model would translate very well into real world environments, but to actually see our silkworms perform at this level is inspiring. The technology is now outperforming the infrastructural capacities, which bodes well for future product, and production, expansion," said Company Founder and CEO, Kim K. Thompson. 

"The fact that the reported yield rates are holding, or improving, has given us the confidence to authorize a doubling of the scale of production. We anticipate this next larger production run will launch in June. We are excited and encouraged to see that our systems are holding up well as we increase the scale of Monster Silk™ production, and we are working with third parties to strengthen the infrastructure to support the increased production," Thompson concluded.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc.

(www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel,
Hansel Capital, LLC.
(720) 288-8495





World's First Monster Silk(TM) Textile Created by Warwick Mills and Kraig Biocraft Laboratories Collaborative Effort



Spider Silk Textile Development Breakthrough

LANSING, Mich., June 18, 2014 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Kraig"), the leading developer of advanced spider silk based fibers, announced today Warwick Mills ("Warwick"), a leader in the engineering and development of advanced technical textiles and protective materials, created the world's first textile utilizing Kraig's genetically engineered spider silk, Monster Silk™.

The first Monster Silk™ textiles are knitted gloves and the first photos are available at the following link:  http://www.kraiglabs.com/spider-silk-textiles/

They are considered to be the first of many textiles that are to be created as part of the Company's joint development agreement with Warwick.

"We have been working with various types of Monster Silk™," stated Charles Howland, President of Warwick. "We find that all of these fibers are compatible with existing yarn processing and textile formation methods. As is expected, fiber consistency is not yet at fill production levels. However, for the current stage of maturity, these silk materials already have good levels of quality and consistency. We have been making jersey knit samples and will start weaving shortly. These small scale trials are key to helping identify, for Kraig Labs, areas for development for upcoming fiber production trials. We are reviewing textile properties of the samples with Kraig staff and exploring the most attractive applications for this fiber. Overall the trails are well underway and we are making good progress toward commercialization."   

"One of the biggest issues facing our Company was creating our first textile and the open question of whether genetically engineered spider silk could be successfully processed using existing textile formation methods," said Company founder and CEO, Kim K. Thompson. "With this successful test, and the creation of the first Monster Silk™ knits, we have established that our genetically engineered spider silk works well with existing manufacturing methods. The creation of these knits is a huge milestone in our progress toward making genetically engineered spider silk available for industrial and consumer applications. The fact that these advanced materials process well on existing machinery will help speed up the development of advanced spider silk textiles."

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel,
Hansel Capital, LLC.
(720) 288-8495

 

PostSubject
#78426  Sticky Note 6 Ways Nature Is Inspiring Human Engineering Eskaminagaga 08/07/14 12:18:23 PM
#76763  Sticky Note Registration Certificate: MONSTER SILK TheEternalChampion 07/02/14 02:23:40 AM
#76519  Sticky Note **FUTURE SOLDIERS MAY WEAR BULLETPROOF SPIDER SILK** TRUTH 06/25/14 12:13:58 PM
#67215  Sticky Note KBLB Delivers 1st Shipment of MS to Warwick Mills ZincFinger 12/09/13 06:25:05 AM
#44280   Very Cool Zenaku. Thank You. oilstrike 05/25/12 12:19:46 PM
#44279   I agree completely. TheOcho 05/25/12 11:23:35 AM
#44278   There are only a few people that are TheOcho 05/25/12 11:20:26 AM
#44277   You mean WHEN KBLB does that? :) dadofduck 05/25/12 09:36:01 AM
#44276   If we had the goods, wouldn't the word ErnD 05/25/12 09:35:51 AM
#44275   Sorry DoD, no PM... Yes that is it rayovac812 05/25/12 09:11:36 AM
#44274   Zincfinger you are wrong. When reading the manshoon1 05/25/12 09:08:07 AM
#44273   Your point is true but totally irrelevant! ZincFinger 05/25/12 08:14:55 AM
#44272   Updated Ibox. Feel free to tell me what TheEternalChampion 05/25/12 02:42:08 AM
#44271   What's REALLY interesting is THIS: The ONLY instances manshoon1 05/25/12 12:54:05 AM
#44270   Unfortunately with the wonders of the Internet, PRs dadofduck 05/25/12 12:38:23 AM
#44269   Your entire argument is based on as ASSUMPTION ZincFinger 05/24/12 10:53:19 PM
#44268   Bedding and outerwear...sounds too nice. You have vision.... rayovac812 05/24/12 09:35:10 PM
#44266   Bedding and outerwear are mega billion dollar markets gamesetmatch101 05/24/12 05:21:07 PM
#44264   I think the first deal will be a Romans828 05/24/12 04:30:45 PM
#44263   That would be nice! When the first Diveintoapool 05/24/12 04:23:28 PM
#44262   Hopefully, by then, you'll be travelling in a Romans828 05/24/12 04:13:24 PM
#44261   ZF I have tried to figure out what shannonwm 05/24/12 04:01:33 PM
#44260   I hope the 2013 show is in Anaheim! Diveintoapool 05/24/12 03:58:03 PM
#44258   The PRs on iHub still include "Dr. David elichen 05/24/12 03:33:14 PM
#44257   Looks like Kim may be heading to the MU_Redskin1 05/24/12 03:31:10 PM
#44254   KIM'S STATEMENT: elichen 05/24/12 02:17:04 PM
#44253   http://www.textileworld.com/Articles/2012/May/Techtextil_North_America_2012_Back Zenaku 05/24/12 02:10:17 PM
#44252   Zenaku, thank you. You are truly an asset Romans828 05/24/12 01:48:54 PM
#44251   One of 5 exhibitors chosen for a statement TheOcho 05/24/12 01:41:47 PM
#44250   http://www.innovationintextiles.com/techtextil-north-america-returns-to-prereces Zenaku 05/24/12 01:24:47 PM
#44249   Here is an article about silk and electronics. TheOcho 05/24/12 01:07:40 PM
#44246   IMO, Kim is interested in partnering with solid, MU_Redskin1 05/24/12 10:49:38 AM
#44245   Never? So I guess KT accidentally wrote a TheOcho 05/24/12 10:40:13 AM
#44243   Hi Mike, Romans828 05/24/12 09:24:10 AM
#44242   Agreed. TheOcho 05/24/12 09:21:14 AM
#44241   Hi Bob, Romans828 05/24/12 09:10:49 AM
#44240   Members of the board of advisers are consulted ZincFinger 05/24/12 07:01:01 AM
#44239   One of my opinions that I have had first mike 05/24/12 01:25:37 AM
#44238   I believe an email was posted from dr TheOcho 05/24/12 12:00:42 AM
#44237   Think that we are using slightly different definitions manshoon1 05/23/12 11:53:11 PM
#44236   Not directors, Board of Scientific Advisors and no, dadofduck 05/23/12 10:30:46 PM
#44235   What is going on with KBLB? PPS is Carry 05/23/12 08:25:58 PM
#44234   First Mike, whiteface88 05/23/12 07:49:59 PM
#44233   Hi Romans828, bananarama 05/23/12 07:09:15 PM
#44232   I was referring to mention in the article Romans828 05/23/12 06:16:43 PM
#44231   I would show your broker. Maybe they do rayovac812 05/23/12 04:56:05 PM
#44230   Happens to me frequently...the playing field is NOT Romans828 05/23/12 04:46:04 PM
#44229   You always do a great job of finding Romans828 05/23/12 04:42:30 PM
#44228   Yeah, I never quite got that. I Diveintoapool 05/23/12 04:33:33 PM
#44227   http://www.upi.com/Science_News/2012/05/23/Chemical-dip-creates-killer-silk/UPI- Zenaku 05/23/12 04:33:04 PM
#44226   Buying in at the low seems to be first mike 05/23/12 02:25:15 PM
#44225   Is Dr. Kaplan still on the Board of elichen 05/23/12 01:45:32 PM
#44224   :D If I had some reserve I Diveintoapool 05/23/12 01:36:58 PM
#44223   I am tired of waiting for it to rayovac812 05/23/12 01:24:43 PM
PostSubject